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CHAPTER 1
INTRODUCTION

1.1

Scope of the Project
This project focuses on production of pattern specific isotopically labeled

phenylalanine (PSAL phenylalanine) (Figure 1.1) and its incorporation into recombinant

Figure 1.1 Phenylalanine with , andpositions labeled with stars and Greek letters.

proteins for characterization of macromolecular complexes. PSAL phenylalanine is a
phenylalanine residue with 13C carbons at every other carbon position within the amino
acid. This will be achieved in three steps: production, incorporation, and macromolecular
complex study. In addition to providing a new reagent, this work defines a method for its
economical and scalable production in E. coli. Further, a broadly applicable method for
incorporating phenylalanine into bacterially expressed recombinant proteins is developed.
1

Specifically labeled phenylalanine will be of great use in characterizing large
macromolecular complexes, including membrane-bound proteins. PSAL phenylalanine,
along with a general incorporation method, will provide structural biologists with a new
method for studying protein-protein or protein-nucleic acid interactions as well as large
macromolecular complexes [1].
Production of pattern specifically labeled amino acids involves genetic
modifications to an E. coli vector to increase the expression of aromatic amino acid
biosynthesis pathway genes. This vector also includes a secretase to secrete the aromatic
into the media for easy retrieval. The vector will be transformed into cells with modified
carbon metabolism to further increase amino acid production. These changes will allow
for targeted labeling of specific atoms within an amino acid residue, allowing for precise
pattern specificity.
Once the production of PSAL phenylalanine is optimized, a general method for its
efficient incorporation is needed. PSAL production using stable isotopes in bacterial
cultures is more economical than the previously proposed synthetic production. This
work provides a widely applicable method for incorporating PSAL phenylalanine into
any recombinant bacterial system. A shikimate inhibitor in combination with amino acid
supplementation leads to >95% labeling of phenylalanine residues within a recombinant
protein.
While there are many potential applications for PSAL phenylalanine labeling, this
work includes preliminary structural studies of the Pth1: peptidyl-tRNA complex. To
illustrate the utility and applicability of this new methodology, PSAL phenylalanine
labeling can be used to study the interaction of phenylalanine residues of the Pth1 protein

2

and the involvement of these residues in forming a complex with its natural substrate,
peptidyl-tRNA. The structural information on the enzyme: substrate interaction of Pth1
with peptidyl-tRNA obtained in this study will facilitate future studies on structure-based
inhibition.

1.2

Macromolecular Interactions
Macromolecular interactions are the basis for biological function and regulation

and are at the forefront of structural biology. These nanomachines are involved in
virtually every life process and include systems such as the proteasome, the nuclear pore
complex, exosomes, polysomes, groEL/ES, spliceosomes, and others. Understanding
these important interactions at the atomic level will, in turn, further our understanding of
disease mechanisms, structure-guided drug design, and gene regulation, all of which are
vital to improving and sustaining health.
Methods exist already for studying macromolecular complexes, such as
fluorescence resonance energy transfer, electron microscopy, x-ray diffraction, small
angle neutron scattering, and nuclear magnetic resonance spectroscopy (NMR)
(Appendix A). Each of these methods has a unique set of advantages and disadvantages
that may be system dependent. For example, X-ray diffraction has been used to study
high resolution structures however not all systems form highly diffracting crystals. NMR
has also been used, but despite technological advancements, a significant size barrier
limits the biomolecular systems that are acceptable for NMR study [2].

3

1.3

Isotope Labeling in NMR Spectroscopy
Isotope labeling plays a critical role in structure determination of biological

molecules. In protein NMR spectroscopy, isotope labeling involves introducing a stable
isotope either uniformly into amino acids within proteins, or at specific sites within an
amino acid residue. These isotopically labeled amino acid probes simplify spectra of
large complexes such that structural and binding information can be obtained. This NMR
technique of introducing a stable isotope into biological amino acid residues is nondestructive to samples, and provides data acquisition within a matter of minutes to hours.
Isotope labeling simplifies the spectra of large molecules, allowing for more complex
samples to be studied. This simplification allows for even complicated integral
membrane protein studies to be pursued [3].
Isotopic labeling for structural biology has advanced dramatically over time.
Uniform enrichment of a protein with 13C or 15N has become a standard technique for
study of large molecular weight proteins [24]. In this way, magnetization is transferred
from a 1H to either 13C or 15N, and sequence assignments can be made [4]. Uniform
labeling was next combined with perdeuteration, or the replacing of hydrogens with
deuterons, to further amplify the isotopic signal by reducing the background by
eliminating the 1H signals. This has also become widely used in the NMR community to
achieve less complicated spectra. Deuteration results in approximately a ten-fold
decrease in relaxation rates for carbon protein spectra, dramatically increasing the
transfer efficiency and narrowing peaks for a high signal-to-noise ratio [5].
Perdeuteration can be achieved by growing cells in deuterated media or by partially
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exchanging the protons for deuterons by resuspending lyophilized protein in deuterated
buffer.

1.3.1

Early NMR Isotope Labeling Methods
Nuclear Magnetic Resonance Spectroscopy was first used for bulk materials in

1946 [6]. In the past 60 years, NMR has expanded to include studies on kinetics,
conductivity, chemical structure, materials science, and medical imaging [6]. In 1950,
the benefit of studying chemical shifts of isotopes was revealed in a study of chemical
shifts in ethanol [7]. This, in combination with increasingly homogenous magnetic
fields, led to the study of interactions between nuclei that result in multiple signals, or
scalar couplings [8]. To further improve signal resolution, Bloch et al. introduced the
idea of excitation of a sample using a radio frequency pulse, leading to a free precession
signal and the formation of a spin echo [9, 10]. Pulse methods then became widely used
by physicists, but complex free induction decay still limited the use of NMR by chemists.
In 1958, Shoolery and Rogers showed the benefit of 1H NMR for studying methyl groups
in steroids [11]. Their work paved the way for organic chemists to begin studying
moderately sized molecules [12, 13]. In 1961, the introduction of the Varian A-60 (see
Figure 1.2) allowed for the major innovation of maintaining a constant signal between the
magnetic field and the applied radio frequency to eliminate drift.

5

Figure 1.2 The Varian A-60 Nuclear Magnetic Resonance Spectrometer (Image courtesy
of the Chemical Heritage Foundation)

This innovation also allowed for standard chemical shift tables of compounds to
be constructed. The study of NOE enhancements, or Nuclear Overhouser Effects [14]
was another major development. This allowed for intense investigations of energy levels
and molecular conformations. The combination of NOE enhancements with 13C NMR
studies made practical observation of 13C carbons feasible [15]. Also in the 1960s,
superconducting magnets were developed by Varian that increased the frequency up to

6

600 MHz [6]. This further increased the complexity of organic compounds available for
study to include peptides, nucleotides, amino acids, and even small proteins, bringing
biochemistry to the forefront of NMR spectroscopy [16, 17]. To overcome increasingly
dilute samples with high noise, time averaging was applied. However, with higher
magnetic fields, too much time was required to increase the signal to observable levels.
It was shown that, by employing the Fourier Transform, a Free Induction Decay (FID)
could be transformed into a spectrum using new computers and software [18, 19].
Hence, FT-NMR was born, signifying a huge leap in NMR technology and allowing for
time dependent studies of samples including relaxation.
The next major development in NMR methodology was 2D spectroscopy, which
involves the Fourier transform of two independent time domains of pulse sequences with
the corresponding spectra being displayed along a two- dimensional frequency plane
[20]. Two-Dimensional NMR Spectroscopy allowed for the study of cross-relaxation
interactions, chemical exchange, and other new advances [21].
By this time, 30 years had passed since the initial development of NMR. Finally,
NMR was becoming sensitive enough to study biopolymers and living systems, including
macromolecular structures. Unfortunately, due to complicated spectra, assignments were
largely subjective. To achieve accurate results, experiments were both many and tedious.
Correlated spectroscopy (COSY) used in conjunction with NOESY and advances in
computer software advanced the study of biopolymers and paved the way for other
biological macromolecules through an examination of atomic interactions based on space
and bonds [22-23]. These advances permitted the first protein structure to be determined
and published without using 13C and 15N isotopes for labeling [24].

7

1.3.2

Residue Type Specific Labeling
Residue type specific isotopic labeling [25] complements NMR advances and

provides many new options for the study of large systems. Residue type specific labeling
is exclusively labeling a specific residue or set of residues within a biological
macromolecule. In this way, a specific active site or key residue can be highlighted in an
NMR spectrum using 13C, 15N, and 2H incorporated isotopes along with NMR
technological advances. Using a limited number of residues, a very large complex can be
simplified enough to solve its structure or determine the binding or catalytic mechanism.

1.4

Selective Isotopic Labeling for Large Macromolecular Complexes
Selective isotope labeling was developed as a technique to overcome the size

barrier for macromolecules to be studied. The increasingly popular ILV (Isoleucine,
Leucine, Valine) methyl labeling method [26] takes advantage of multiple equivalent
protons on methyl groups to study very large systems, but is dependent on the presence of
ILV residues and necessitates deuteration [2, 27-30]. Another approach involving
aromatic amino acid incorporation into recombinant proteins has been achieved using
SAIL methods [31]. This method uses in vitro expression, which can be very expensive
and sometimes unreliable. Despite limitations of complexity and cost, SAIL has been
used to study large proteins, such as the 20s proteasome (670 kDa) [32]. New
advancements in techniques for labeling and studying macromolecular complexes will
make macromolecular complex study faster, cheaper, and more readily available. This
will pave the way for better understanding of protein-protein interactions and mechanistic
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information on biological regulatory functions; information that is critical to drug
development and, therefore, human health.

1.4.1

Fluorinated Amino Acid Labeling
To expand on isotopes available for NMR study, amino acids can be fluorinated

such that one of the atoms in a natural amino acid is replaced with a fluorine atom. This
unnatural fluorinated amino acid can be easily identified in an NMR spectrum. Using
fluorine as a probe aids in identification of binding sites or the location of specific
residues within a protein and its proximity to other labeled residues.
One such system aimed at simplifying spectra to increase NMR size barriers was
the use of fluorinated tryptophans. Problems exist in the use of fluorinated aromatic
amino acids, which have been employed as highly sensitive probes for NMR studies of
large systems, since these analogues can be toxic to wild-type cells and can necessitate
unique auxotrophic cell strains [33].

1.4.2

ILV Methyl Labeling
One of the most common isotopic labeling strategies for large systems takes

advantage of isoleucine, leucine, and valine (ILV) amino acids [26]. This labeling
strategy utilizes selective incorporation of 1H-13C methyl groups into a highly deuterated
background. Since ILV residues are plentiful in proteins, this provides a large number of
probes for studying proteins and complexes using NMR. Thus, ILV methyl labeling has
increased the size limit for NMR studies of protein structure, dynamics, and
intermolecular interactions. The study of ILV methyl resonances benefits from multiple
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equivalent protons contributing to an increased signal of interest, rapid rotation around
the methyl axis that decreases the effective correlation time, and distinct 1H-13C
correlations within well-defined chemical shift regions [27].
Further, in addition to the production of specifically labeled ILV residues, methylTROSY experiments (methyl-transverse relaxation optimized spectroscopy) have led to
higher sensitivity and simplification of NMR experiments [30]. ILV methyl labeling
strategies have allowed for the measurement of structurally informative NOEs as well as
the dynamics of numerous large systems, including those up to 800 kDa in molecular
weight. These include the 370-residue single polypeptide chain maltose-binding protein
(MBP, 24 kDa), the high mobility group nucleosomal protein-2 complex (230 kDa), and
monomeric malate synthase G (82 kDa), among others [2, 28-30].

1.4.3

Alanine Threonine Methyl Labeling
Similar to the isoleucine, leucine, and valine residues, alanine residues are the

most common amino acid and are widely distributed throughout proteins, making them
valuable residues for specific labeling [34]. Alanine residues are also commonly used as
replacement residues in mutagenesis due to their small size and ease of mutation [35, 36].
Moreover, alanine is one of the most common residues found at molecular interfaces
[37]. As an extension of ILV methyl labeling, Isaacson et al. [35] developed a method
for synthesizing and incorporating13C-2H alanine into recombinant proteins with a highly
deuterated background. This labeling method results in >75% labeling of alanine residues
and can be used in conjunction with ILV methyl labeling if either of the two methods
alone do not provide enough information to characterize a complex.
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In addition, alanine labeling has been used to study a 10kDa ubiquitin-like
domain with >75% labeling incorporation [36]. This method was improved with the
addition of α-ketoisovalerate-d7, succinate-d4, and L-isoleucine-d10 to the labeled alanine
in a perdeuterated background. This reduces the background labeling significantly by
suppressing the alternative alanine metabolic pathways [38].
Threonine residues are another natural progression of isotopic labeling schemes as
these residues are commonly found at protein-RNA and protein-DNA binding interfaces.
Threonine labeling was used to study protein-RNA complexes using E. coli with 2-13C
glycerol as the sole carbon source in the presence of deuterated isoketovalerate [39].
This labeling scheme was also applied to the 670 kDa proteasome, as well as proteinRNA complexes [40]. Threonine labeling also utilized over supplementation of lysine,
methionine, and isoleucine residues to suppress scrambling.
Accordingly, these residues have become useful components of many residuelabeling schemes. However, despite these advantages, as well as the abundance of
alanine and threonine in numerous biosynthetic pathways, isotopic scrambling has still
been difficult to overcome, and additional probes are needed [36].

1.5

Aromatic Amino Acid Isotopic Labeling
Isotopic Labeling of the aromatic residues phenylalanine, tyrosine, and tryptophan

is a natural progression from current and past techniques. This labeling technique is a
tool to be used primarily with NMR Spectroscopy. This involves introducing isotopically
labeled aromatic amino acids into a biological macromolecule to highlight these residues
in an NMR spectrum.
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1.5.1

Benefits of Aromatic Amino Acids
As with methyls, aromatic amino acids are generally found in the hydrophobic

core of a protein. Therefore, they hold a wealth of structural information. In addition,
aromatics are often found in protein “hot spots” [41, 42]. Accordingly, certain classes of
proteins take advantage of aromatic residues and interactions, including carbohydrateand DNA- binding proteins. When studied at binding interfaces, aromatics provide a
means of highlighting macromolecular complex formation [42-47]. Additional
advantages of aromatic labeling include the following:


Distinct 13C side-chain chemical shifts



Multiple magnetically equivalent protons leading to increased signal strength
in important side-chain positions



Ring flipping, which reduces the apparent correlation time to circumvent
relaxation-related size barriers



Ease and efficiency of isotopic labeling (presented herein)

Another tremendous benefit of aromatic labeling is compatibility with ILV methyl
labeling. Combining these strategies extends the amount of information that is gained
beyond methyl-methyl interactions to aromatic-aromatic and aromatic-methyl
interactions. Thus, using labeled aromatics alone as well as in conjunction with ILV
labeling allows for more meaningful studies of extremely large bio-macromolecular
complexes.
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1.5.2

Production of Aromatic Amino Acids
Aromatic amino acids can be produced in multiple ways. While synthetic

production of these amino acids is possible, it is much more expensive than bacterial
fermentation methods with modified bacteria. Another method of isolating aromatic
amino acids is by extracting protein rich sources such as algae using industrial processes
[48]. Fermentation methods are currently the most economical for large-scale production
of L-phenylalanine [49]. Strains of E. coli or C. glutamicum are the most commonly used
bacterial organisms for recombinant production. Aromatic amino acids are primarily
produced commercially for human food additives [50] and include phenylalanine,
tyrosine, and tryptophan (Figure 1.3). Aromatic amino acids are valuable in both the
food and pharmaceutical industries, such as in the production of aspartame from
phenylalanine and the anti-Parkinson's drug L-dopa from tyrosine [49].

L-Phenylalanine

L-Tyrosine

L-Tryptophan

Figure 1.3 The three aromatic amino acids—L-phenylalanine, L-tyrosine, and Ltryptophan—including all implicit hydrogen molecules
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The three aromatic amino acids, phenylalanine, tyrosine, and tryptophan are all
produced commercially for varied commercial and pharmaceutical products. Of the three
aromatic amino acids, phenylalanine is in the largest demand, mainly because of its use in
the production of the artificial sweetener aspartame [51]. It is also used as an additive in
foods and as a starting material for pharmaceutical companies, with gross sales of the
amino acid in the billions of dollars annually [52]. Recombinant methods have resulted
in production of aromatic amino acids through the use of random mutagenesis or targeted
metabolic engineering, but these methods have not yet produced phenylalanine efficiently
[53].

1.5.3

Metabolic Pathway for Aromatic Amino Acid Production
Recombinant production of aromatic amino acids was first achieved using random

mutagenesis and observing the increases or decreases in the concentrations of desired
products [51]. Once aromatic amino acid biosynthesis pathways were deduced (Figure
1.4), genetic modifications that added enzymes to shuttle production from metabolites to
the aromatic amino acids dramatically increased their production (Figure 1.5).
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Figure 1.4 KEGG pathway of phenylalanine, tyrosine, and tryptophan biosynthesis [54].
Aromatic amino acids (red), enzymes of interest include ydiB (dark blue) 1.1.1.282, aroC
(light blue) 4.2.3.5, aroK (orange) 2.7.1.71, pheA (purple) 4.2.1.51, and tyrB (green)
2.6.1.57.
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Using the aromatic amino acid biosynthesis pathway as a guide, genes responsible
for overcoming enzymatic bottlenecks were selected as targets for genetic manipulation.
Enzymatic bottlenecks in the process are seen before and after shikimate in the common
pathway. To overcome these bottlenecks, we selected the genes ydiB and aroK before and
after shikimate. Each of these enzymes has two redundant genes. Starting with shikimate
dehydrogenase and moving to shikimate, both ydiB and aroE code for this enzyme. While
aroE is more commonly found in E. coli, it is feedback inhibited by shikimate. Similarly,
the more common aroL is feedback inhibited by tyrosine. What is interesting about these
genes is that, while they have very little sequence homology, they have the same fold and
function. We chose the genes that weren’t feedback inhibited to clone into our vector. We
also cloned aroC and tyrB to use, as they were some of the last steps in the pathway.
Combinations of genes, such as aroC and ydiB, had a greater impact on aromatic
biosynthesis than either of the genes did when applied alone [55].
It was also necessary to map the progress of a
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C label from glycerol to

phenylalanine. The labeling of the second carbon in glycerol follows a straightforward
course to phospoenolpyruvate. Meanwhile, erythrose-4-phosphate derives its labels from
labeled phospoenolpyruvate in two rounds of gluconeogenesis, which is enhanced by the
presence of the tktA gene in the original vector (Figure 1.6).
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Figure 1.5 Simplified pathway from 2-13C glycerol to phenylalanine and tyrosine.
Carbons in red indicate 13C carbons. Genes in green are those that have been cloned into
the vector, and bottlenecks are indicated in blue. "X" indicates the site at which the
glyphosate inhibitor is active.
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Figure 1.6 Erythrose-4-phosphate is labeled from phosphoenolpyruvate. Carbons
in red indicate 13C carbons.

1.5.4

Current Aromatic Amino Acid Labeling Techniques
Recombinant production of phenylalanine through E. coli has been achieved, but

has not yet been made efficient. Using organic synthesis to produce sodium succinate, 10
liters of deuterated media, and a 6 column purification process that takes more than 2
weeks, the Lemaster laboratory was able to produce 0.55 grams of uniform 2H, 15N
phenylalanine [56]. This method was then improved to include specifically labeled
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phenylalanine through the use of 1-13C acetate, achieving 70% carbon labeling of the
carbonyl, para, or meta carbons in a phenylalanine residue [57].
Taking advantage of key metabolic pathway genes, modifications to the aromatic
amino acid biosynthesis pathway genes aroA (EPSP synthase), aroC (chorismaste
synthase), aroL (shikimate kinse), and aroB (DHQ synthase), resulted in greater
production of phenylalanine in a recombinant system with glucose as the carbon source.
Using isotopically labeled glucose, full isotopically labeled aromatic amino acids could
be produced in a recombinant system [53]. Modifications to the shikimate pathway also
increased the presence of aromatic precursors, further increasing aromatic amino acid
production [58]. Combinations of aromatic amino acid pathway genes led to further
increases in aromatic amino acid production, specifically for tyrosine. Some of the best
aromatic producing genes included aroK (shikimate kinase) and ydiB (shikimate
dehydrogenase) [55, 59].

1.5.5

Pattern Specific Aromatic Labeling (PSAL) of Phenylalanine
PSAL labeling of phenylalanine is introducing 13C carbons into specific sites

within a phenylalanine residue. Similar to ILV methyl labeling, the advantages of PSAL
phenylalanine include simplified NMR spectra and multiple magnetically equivalent 1H
protons, thereby leading to increased signal strength. Also, the reduction of the apparent
correlation time through ring flipping circumvents relaxation rate size barriers, allowing
for studies beyond the current observational limits. Compatible with ILV methyl
labeling, aromatic-aromatic and aromatic-methyl interactions will be observable in NMR
spectra using PSAL phenylalanine labeling in addition to methyl-methyl interactions.
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This allows for better characterization of extremely large systems. The method presented
for PSAL phenylalanine is primarily for use in NMR spectroscopy (including membrane
protein studies), though other areas, such as mass spectrometry proteomics-driven
proteomics using stable isotopic labeling in cell culture, will also benefit from this
approach [31].

1.5.6

Current Limits of Phenylalanine Labeling
A limitation to residue type-specific labeling arises from the incorporation of

selectively labeled phenylalanine into recombinantly expressed proteins. Isotope
incorporation is often achieved by adding labeled amino acids of interest to bacterial
growth media before protein expression. Another possibility is in vitro expression
following the SAIL methods [31]. However, in vitro expression is expensive, not always
reliable, and not necessarily scalable to milligram quantities, although considerable
improvements have recently been reported over originally existing protocols. This is a
limitation that must be overcome if specifically labeled phenylalanine is to be widely
used for structural biology.

1.6

Applications of PSAL Phenylalanine Labeling
Once pattern-specific aromatic amino acids are produced in sufficient quantities

for incorporation into a protein and the hurdles of 13C incorporation have been solved,
they can be used to study macromolecular complexes. Ideal systems for PSAL
phenylalanine labeling include those with phenylalanine residues at binding interfaces or
catalytic sites. Other systems that do not have any isoleucine, leucine, or valine residues
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present that cannot use ILV methyl labeling will benefit from PSAL phenylalanine
labeling. To develop and optimize a method for incorporation of PSAL phenylalanine
into proteins, a model protein was used.

1.6.1

Ubiquitin as a Model Protein
Ubiquitin is a highly conserved eukaryotic protein with 76 amino acid residues

corresponding to 8.6 kDa. Ubiquitin has 2 phenylalanine residues, 2 tyrosine residues,
and no tryptophans; it also highly over-expresses (56 mg/L) in M9 minimal media [60,
61]. Ubiquitin has been used as a model protein for some time due to its ease of
expression and purification. Much is known of this protein and how it interacts with
other domains [60-62]. Because this protein has been so often used as a model, ubiquitin
was an easy choice for the protein that was used to prove that the incorporation of
pattern-specific labeling of aromatic amino acids was feasible (Figure 1.7).
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Figure 1.7 Human ubiquitin protein, PDBID: 1ubq

Once a method is optimized in a well-behaved systems such as ubiquitin, it will
be necessary to confirm broad applicability of the method by applying it to a system that
is not so well behaved. For instance, the peptidyl-tRNA hydrolase protein in complex
with peptidyl-tRNA is a complex that has yet to be fully characterized at a high
resolution due to its size and the difficulty in its crystallization. This complex is a prime
target for pattern-specific isotopic labeling of aromatic amino acids.

1.6.2

Pth1 in Complex with Peptidyl-tRNA
Pth1 (Figure 1.8) is an essential bacterial enzyme that recycles peptidyl-tRNA

during protein biosynthesis when the ribosome has stalled. Pth1 hydrolyzes
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Figure 1.8 E. coli Pth1 (PDBID: 2Pth1) with the peptide channel highlighted in orange,
the catalytic H20 residue in red, and the phenylalanine residues in blue

peptidyl-tRNA, freeing the tRNA to be used for further protein biosynthesis. This
protein is highly conserved across bacterial species and has no essential eukaryotic
homolog, making it a high value drug target. Pth1 [63] consists of 194 residues
corresponding to 21 kDa, including 11 phenylalanines, 2 tyrosines, and 2 tryptophan
residues and over-expresses at lower levels (8 mg/L) in M9. The crystal structure of wild
type of E. coli Pth1 has been solved [64] as has the structure of Pseudomonas aeruginosa
Pth1[65], but the structure of the complex remains relatively unknown. Pth1 bound to its
natural substrate, peptidyl-tRNA hydrolase, has not been studied in its entirety due to size
constraints and crystallization difficulties. This is likely caused in part by the
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conformational plasticity of tRNA, complicating structural studies. Despite this, neutron
diffraction of the peptidyl-tRNA hydrolase protein has been achieved, and
crystallographic studies of peptidyl-tRNA hydrolase variants were begun to prepare for
the possibility of neutron diffraction studies of isotopically labeled tRNA in complex
with peptidyl-tRNA hydrolase. A mutant of Pth1 in which the catalytic histidine residue
is replaced with arginine (H20R) allows for substrate binding without cleavage [66], so
that the bound complex can be effectively studied. Yet, this condition has not been fully
characterized. The Pth1 mutant has been shown by chemical shift perturbation mapping
and CD spectroscopy to have no effect on the folding of the protein. Because this protein
has great potential as an antibiotic drug target, many studies have been done on the apoprotein, including the determination of the proposed tRNA and peptide binding regions
[66-71]. However, information on the enzyme-substrate complex is scarce.
One such study on a partial substrate proposes that the tRNA TC loop wraps
around the Pth1 protein in a way that contradicts our preliminary data [72]. Studying
Pth1 bound to the full, natural peptidyl-tRNA substrate will reveal the exact position of
peptidyl-tRNA in the enzyme substrate complex, which will be vital for the design of
Pth1 targeted anti-bacterials. In addition, deducing the mechanism of action for this
enzyme will be key to drug development. This system is an application of the PSAL
method in that both the Pth1 protein and/or the tRNA could be labeled with isotopes:
PSAL phenylalanine residues could be incorporated into the complex, in the tRNA, or in
the peptide that is attached to the tRNA. As this system is very large and has not yet been
fully characterized, it is only an application of the PSAL labeling and is not a model
system. Additional proteins with phenylalanine residues in active sites or those without
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ILV residues, necessitating a novel residue specific labeling system will benefit from this
system. An example of this is the Scytovirin protein. This protein has 95 amino acid
residues in two conserved domains, yet has no isoleucine, leucine, or valine residues.
This protein does, however, have critical phenylalanine residues involved in carbohydrate
binding [98]. This is indicative of many systems that need new methods of labeling for
structural study.
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CHAPTER 2

METHODOLOGY

2.1

Genetic Modifications

2.1.1

Source Vector and Cells
Production of uniform isotopically labeled phenylalanine has been achieved. To

produce pattern specific isotopically labeled amino acids, genetic modifications were
necessary. Using the aromatic amino acid biosynthesis pathway, Frost et al. generated a
bacterial vector that produced an unnatural molecule, para-hydroxy benzoic acid (PHB),
with phenylalanine as an undesirable side-product [53, 58]. The bacterial vector also
included a gene coding for a secretase that secreted the product of interest into the media
for easy recovery. The PHB producing system [53] was modified to divert production
from PHB to the minor product, phenylalanine. We replaced the gene that produced PHB
[73] with other genes coding for enzymes in the aromatic amino acid biosynthesis
pathway. The original vector used, pp JB2.274, contained the following genes: aroF, 1.3
kb coding for DAHP synthase, ubiC, 0.58 kb coding for chorismate lyase, serA, 1.9 kb
coding for phosphoglyerate dehydrogenase, and tktA, 2.2kb, coding for transketolase.
The vector also included a Kanamycin resistance cassette along with a lac promoter
(Figure 2.1) [53, 58, 73]. To achieve labeling of particular atoms within the aromatic
ring, carbon sources with specific isotopic incorporation were used.
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Figure 2.1 p JB2.274 plasmid. Arrows indicate direction of gene.

For 13C isotopic incorporation of the  and ζ position of phenylalanine side chains, 2-13C
glycerol as the sole carbon source was used. This starting material results in an
approximate cost of $375.00 per gram of PSAL phenylalanine which is less than more
than 10 times the cost of synthetic production [51]. Commercial value of PSAL
phenylalanine was estimated at $20,000 per gram.
2.1.2

Vector Sequencing
To make genetic modifications to the p JB2.274 vector, it was necessary to

sequence it fully such that changes would be straight forward. Sequencing of the vector
was accomplished by designing and ordering primers that allowed for an overlap of
sequence to confirm the placement and accuracy of the plasmid (Figure 2.2). Sequencing
primers were designed such that there were 300 base pairs between the 3' end of the first
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primer and the end of the existing sequence. This way, there was plenty of space for the
polymerase to bind and still have overlap of the new sequence with the old to prevent any
holes in the sequence. Primers were also designed to be an average of 18 base pairs in
length, with a melting temperature (Tm) of 56°. This was accomplished by changing the
number of bases such that the GC content would give the appropriate Tm.

2.1.3

Removal of the ubiC Gene

Figure 2.2 Sequencing of the pp JB2.274 vector for confirming where the genes and
restriction digests are for ease in genetic modifications. The numbers indicate the
number of bases overlapping in the colored blocks between the sequence reads

The ubiC gene shuttling production towards para-hydroxy benzoic acid was
removed to allow for more production of aromatics to be shuttled towards the aromatic
amino acids and to stop production of para-hydroxy benzoic acid (Figure 2.3).
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Figure 2.3 Metabolic pathway to para-hydroxy benzoic acid. Taken from [74].
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The ubiC gene was flanked with the restriction sites XbaI and EcoRI (Figure 2.4).

Figure 2.4 Splice sites in pp JB2.274 and pET-28. XbaI, EcoRI and SacI sites were used
to cut out the ubiC gene and cut in tyrB, aroC genes.

Unfortunately, because there were many EcoRI sites in the p JB2.274 vector, the EcoRI
site could not be used to remove the ubiC gene. Instead, a unique site near the end of the
ubic gene, SacI was used. An added benefit of including the section of the plasmid
upstream of the gene is that it included the promoter for the gene such that a new one
would not have to be added. The region from SacI to XbaI including the promoter and
UbiC gene was removed and ligated into a pET-28 vector with the SacI to XbaI section
removed (Figure 2.4).
Each of the ingredients in the general restriction digest recipe (Table 2.1) were
added and the mixture was briefly vortexed and spun at room temperature. The reaction
mixture was then incubated at 37° C for 30 minutes. Next 6x of loading dye was added if
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Table 2.1 General Restriction Digest Recipe
General Restriction Digest:
10X Buffer
DNA
Fast Digest Enzymes
dH20

2 uL
~500 ng
1 uL each
to 20 uL

the 10x buffer did not already contain dye, and the samples were run on a 10% agarose
gel (Appendix D) at 120 mA for approximately 20 minutes, or until good separation of

Pet28

Sac/Xba1

Nde1
Pet28/Ubic
Sac1
Pet28/Ubic

Ladder
Pet28/Ubic

bands was observable. An example of a DNA gel is shown in Figure 2.5.

Figure 2.5 DNA gel with large pieces of pET-28 cut out to remove the added ubiC
gene at XbaI and EcoRI sites. The smaller pieces (underlined in red) are indicative of
proper ligation at a previous step.
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2.1.4

Addition of aroC and tyrB Genes
After running the digested DNA on an agarose gel, the bands including the DNA

to be spliced were cut out of the gel with a razor blade and purified using a GeneJET
(Thermo Scientific, Pittsburgh PA, USA) gel extraction kit according to the
manufacturer’s protocol. After DNA gel purification, the genes could be spliced back
together in the desired manner using DNA ligase. Once the UbiC gene was in the pET28 vector, other genes could be spliced in using the EcoRI and XbaI sites according to the
general protocol in Table 2.2.

Table 2.2 General Ligation Protocol
General Ligation Protocol
10x Ligation Buffer
Large Fragment
Small Fragment
T4 DNA Ligase
Water, nuclease free

2 uL
3 uL
9 uL
1 uL
to 20 uL

Combine the above, vortex, spin, and incubate for 1 hour at 22 °C.

The genes spliced into the p JB2.274 vector were aroC (coding for chorismate
synthase), tyrB (coding for aminotransferase), and trpE/D to promote the production of
phenylalanine, tyrosine, and tryptophan, respectively [75-77]. (A truncated aromatic
amino acid biosynthesis pathway figure is shown in Figure 1.5). Primers were designed
that included the EcoRI and XbaI sites within the primer to amplify each of these genes
(Table 2.3). Genes were amplified using polymerase chain reaction (PCR) (Table 2.4).
It is imperative that the TAQ buffers and DNA template and primers were thawed prior
to mixing, and that accurate volumes were used. During the thermocycling, step 2 (95 °C
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for 2 min from table 4) is the initial DNA melting step, followed by annealing (55 °C for
2 min) and elongation occurs in step 4 (72 °C for 2 min). The number of cycles was
optimized at 24. Less cycles resulted in too little DNA produced, while more cycles
resulted in mutations within the gene. Five microliters of the PCR product was run on an
agarose gel to confirm the correct size of DNA was amplified.

Table 2.3 Primers

Name
ubiCS
002ubiCA
003ubiC
004ubiC
ubiC005
ubiC006
ubiC007
008ubiC
009ubiC
010ubiC
011ubiC
012ubiC
013ubiC
014ubiC
015ubiC
016ubiC
017ubiC
018ubiC
019ubiC
020trpE
021trpE
022trpD
023trpD
024AroC
025AroC
026tyrB
027tyrB

Sequence
5'-CTGCAGGCAATGAAAGCTA-3'
5'-TTCGCGGATCATCGTCCA-3'
5'-AAA ACG CGC AAG TCA GTG A-3'
5'-CGC TGT CGT CAA GTC GTT-3'
5'-ATTGGCTTCCGGCACGC-3'
5'-TCGCGGGTCAGGGCAAT-3'
5'-TGATCTGACTTTGACTTA-3'
5'-GACGCTGAAATTGCCCTG-3'
5'-CCTAACGGCGTTTTACCC-3'
5'-TCCGGCAGAGCTGCTGT-3'
5'-TCTGGAATATGCTCGTCG-3'
5'-AAAGACTGCGCCGGTCA-3'
5'-TCGTAATCATGTCATAG-3'
5'-CCACCGTTGATATATCCC-3'
5'-GTAGTGGATGTAGTTAC-3'
5'-GTACCAATATGACCGTAG-3'
5'-CTTAATCGCAGGCGGGAA-3'
5'-CTCGCGTAAAAGCATTTCA-3'
5'-GCGCCTTATCCGGTAACT-3'
5'-CGC GTT CTA CGC TTC CC-3'
5'-CTT CAA AGC CAG CGA CCA-3'
5'-TCATCCATGCCGCCGCT-3'
5'-AAACGCGAACCCTGTTCAA-3'
5'-CACGAATTCATGTTGTCTTTAAGGTATTTGAC-3'
5'-AGAACGTAAAAACGAGGTTTGATAATCTAGACAC-3'
5'-CACGAATTCGTGTTTCAAAAAGTTGACGCC-3'
5'-GTGTCTAGATCATTACATCACCGCAGCAAAC-3'
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Purpose
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*sequencing
*amplification aroC
*amplification aroC
*amplification tyrB
*amplification tyrB

028tyrB
029trpD
030trpD
031
032
033
034
035trpD
036tyrB
037trpE
038ydiBf
039ydiBr
040arokf
041arokr
042xhof
043xhor
044petUP
045
045ydiBr2
046aroKr2
047xhof2
048xhor2
048trpEf
049trpEr

5'-GTG TCTAGA TTATCAA ACC TCG TTT TTA CGT TCT-3'
5'-CAC TAT AGGG GGA ATT GTG-3'
5'-CCG CGT GGC ACA AC-3'
5'-AAAACTGGAAGGAAAAGATGGCGATAGAG-3'
5'-CTCTATCGCCATCTTTTCCTTCCAGTTTT-3'
5'-GTC GGA TTC TTG AGCTTA-3'
5'-ATG CTC GTTTGCGATAGT-3'
5'-AAACCTATCCCATAGCTGG-3'
5'-ACGTC TCTAGA TCA TTA CAT CAC CGC AGC AAA-3'
5'-AATACCTAGGCAAAAGGAC-3'
5’-CAAAATACGAATT-3'
5'-AAAAAGAGCTCCTCAGGCACCGAACCCCATGACCT-3'
5'-AAAAATCTAGAAAGGAGGAACAGACATGGCAGAGA
AACGCAATATCTTTC-3'
5'-AAAAAGAGCTCTTAGTTGCTTTCCAGCATGTGAATAA-3'
5'-CTGCTTTCGCTGCGAGCTCGTCAGCATTACC-3'
5'-GGTAATGCTGACGAGCTCGCAGCGAAAGCAG-3'
5'-ATGCGTCCGGCGTAGA-3'
5'-CGT CAG GTG GCA CTT TTC G-3'
5'-AAAAACTCGAGTCAGGCACCGAACCCCATGACCT-3'
5’AAAAACTCGAGTTAGTTGCTTTCCAGCATGTGAATAA3’
5'-CGGGATATTAAGCTCGAGAATCCGACGCAAAC-3'
5'-GTTTGCGTCGGATTCTCGAGCTTAATATCCCG-3'
5'-CAC GAA TTC ATG GGC AGC CAT C-3'
5'-GTG TCT AGA TCA TTA TAC TCT ATT CAA GAA-3'

*correction of #26
*sequencing
*sequencing
mutagenesis AroC
mutagenesis AroC
ubiC/AroC/tryB
*sequencing
*sequencing
*amplification
*sequencing
*amplification yidB
*amplification ydiB
*amplification aroK
*amplification aroK
*xho site
*xho site
* ydiB/aroK
*sequencing
*correct ydiBr
*fix aroKr
*xho site
*xho site
*amplification
trpE/D

Table 2.4 General PCR Protocol

General PCR Amplification Protocol
10x TAQ Buffer
5 uL
2 mM dNTP mix
5 uL
Forward Primer (100 μM)
1.25 uL
Reverse Primer (100 μM)
1.25 uL
25 mM MgCl
4 uL
Template DNA
2 uL
Ultra Pure Water
30.5 uL
TAQ polymerase
1 uL

Thermocyling Parameters
1. 95 °C
3 min
2. 95 °C
2 min
3. 55 °C
2 min
4. 72 °C
2 min
5. Go to step 2, repeat 24 x
6. 72 °C
7 min
7. 4 °C
10 hours

The PCR product was then purified using a GeneJET (Thermo Scientific,
Pittsburgh PA, USA) PCR Purification Kit and cut with the restriction sites imbedded
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into the primers. This DNA was ligated into the pET-28 vector previously cut with the
same restriction enzymes. The small piece (gene to be inserted) and the large piece (the
cut pET vector) were both manually cut out of an agarose gel, purified, and then ligated
together before transformation into JM109 cells. DNA was transformed as follows: 2 uL
of plasmid DNA was combined with 50 uL of whole cells in a 14 mL polystyrene Falcon
tube (Fisher Scientific, Waltham, MA, USA) and allowed to incubate on ice for 30
minutes. The tube was then heated to 42 °C for 50 seconds, followed by 2 minutes on
ice. Next 1 mL of Luria Broth was added to the tube and allowed to incubate while
shaking at 37 °C for 1 hour. Fifty microliters of the culture was then spread onto an
agarose plate including 30 μg/mL of Kanamycin and incubated at 37 °C for 16 hours.
The colonies produced were grown overnight in LB media in the presence of
antibiotics before a DNA mini-prep was performed according to standard biological
methods. Vector DNA was sent for sequencing to confirm the proper placement, fidelity,
and sequence of the modified genes. If the gene was absent, alternate colonies could be
sent for sequencing. Incorrect cloning could be due to the vector not being inserted into
the gene at all, or sometimes by incorrect gene sequence due to mutations in the gene
from too many PCR cycles. If this is the reason, fewer number of cycles or a higher
fidelity DNA polymerase usually remedies this problem.
After confirmation of correct genetic sequence, these vectors were transformed
(using standard biochemical methods) into JB161 cells that were made competent using
calcium chloride.
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2.1.5

Transformation using Calcium Chloride
Fifty milliliters of LB medium was inoculated with a single colony of E. coli

cells. This culture was grown at 37° C with shaking until reaching an OD600 of 0.4.
While the culture was growing, two 50 mL beakers were put on ice at -20 ° C along with
20 eppendorf tubes. When the OD600 of 0.4 was achieved, the cultures were aliquoted
into falcon tubes and put on ice for 10 minutes. This culture was then centrifuged for 7
minutes at 2100 g at 4 ° C. The soup was discarded and pellet resuspended with 10 mL
of ice cold CaCl2. The culture was then centrifuged again for 5 minutes at 1300 g at
4 °C. The soup was again discarded and pellet resuspended in 10 mL of ice cold CaCl2.
The cells were put on ice for 30 minutes before a final centrifugation at 1300 g at 4 ° C.
The soup was discarded and cells resuspended in 2 mL of ice cold CaCl2. Finally, 100
µL of the cell stock was aliquoted into 1.5 mL eppendorf tubes previously put on ice.
These cells were stored at -80 ° C until ready for use.

2.1.6

Addition of tyrB and aroK genes
To further increase the aromatic production, additional genes were added to each

of the three existing modifications. Lutke-Everslohet et. al found that certain
combinations of genes reduced enzymatic bottlenecks in the aromatic amino acid
biosynthesis pathway, mainly genes ydiB(coding for shikimate dehydrogenase) and aroK
(coding for shikimate kinase) [55]. These genes were amplified using primers with
imbedded restriction sites XhoI and XbaI. The XbaI site at the end of the previously
added genes was already present in the p JB2.274 vector, but the XhoI site had to be
added. Mutagenesis was performed using primers MCM0047 and MCM0048 listed in
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table 2.3 to modify the existing vector to include the XhoI site needed to add in these two
additional genes. An example of a mutagenesis protocol is shown in Table 2.5.

Table 2.5 Mutagenesis Recipe and PCR conditions
Site Directed Mutagenesis Reaction:
5 µL of 10X reaction buffer
1.5 µL of DNA (~ 50 µg/mL)
2 µL of Forward Primer
2 µL of Reverse Primer
1 µL of dNTP
1.5 µL of QuickSolution™ reagent
37 µL of dH20 to reach 50 µL reaction volume
0.9 µL of QuickChange™ Lightning enzyme
Mutagenesis PCR Conditions:
Step 1: 95 °C 4 min
Step 2: 95 °C 2 min
Step 3: 64 °C 70 sec
Step 4: 68 °C 5 min
Step 5: 68 °C 7 min
Go back to Step 2, Repeat 18 times
Step 6: 4 °C
10 hours

2.1.7

P-Prime Cloning Kit
For ease of cloning, a p-prime cloning kit (Agilent, Santa Clara, CA) was used to

ligate the aroK and ydiB genes from the PCR product before ligating into the pp JB2.274
cloning vector (see Figure 2.6). One microliter of the p-prime cloning vector was added
to 4 µL of the purified PCR product in addition to 5 µL of the p-prime ligation
mastermix. This mixture was incubated on ice for 30 minutes before 7 µL of the mix was
transformed into 70 µL of JM109 cells. These cells were plated onto LB plates in the
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presence of 50 mg/mL X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside)
and 100 mM IPTG. Colonies with the insert glowed green under UV light.

Figure 2.6 pPrime Cloning Vector Map
These genes were also confirmed with sequencing using primers listed in the table.
Again, the production of aromatics was confirmed with UV spectrometry.

2.1.8

Time Studies to Compare Variants
Once the vectors were transformed into competent JB161 cells with altered

carbon metabolism, it was necessary to observe the change in aromatic production.
Aromatic production was detected using UV absorbance at 280 nm (Figure 2.7).
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Figure 2.7 UV wavelength scan from 240 to 315 nM, with the original p JB2.274 vector
in blue, and the variants constructed in grey and red. PHB absorbs at 245 nm,
phenylalanine around 260 nm. The tyrBaroK variant in red had the highest phenylalanine
production.

Time studies were performed to determine the optimal time of collection of the productenriched media to optimize the yield of phenylalanine. E. coli JB161 cells were
transformed with vectors containing different combinations of phenylalanine metabolism
enhancing genes. They were grown over a period of days in minimal media. Relative
aromatic production was quantified using UV absorbance at 280 nm. The optimal time
of production for PHB in the Frost system was 72 hours [53]. Aromatic production was
quantified at 6 hour intervals beginning at initial resuspension and continued for 96
hours. Other variables studied to optimize phenylalanine production included: addition
of iron to the media, oxygen restriction, growth temperatures, and harvest time. These
conditions have been shown previously to affect the aromatic production [78].
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2.2

Confirmation of Phenylalanine

2.2.1

UV Spectroscopy
For a rough quantification of phenylalanine from bacterial culture media, UV

spectroscopy was used (Beckman DU 650 Spectrophotometer). First the supernatant was
clarified using centrifugation at 4,000 rpm for 30 seconds. The supernatant was then
diluted with water such that a reading of under ~1.0 was observable in the 260 nm range
of a UV wavelength scan. Prior to reading the sample, a blank sample of growth media
was scanned to reduce background. This value was then normalized against a standard
UV absorbance curve for phenylalanine (Figure 2.8) to quantify the phenylalanine within
the sample.

Absorbance at 260 nm

0.7
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0.5
0.4
0.3
Phe standard

0.2
0.1
0
0
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Figure 2.8 Absorbance at 260 nm of varying concentrations of phenylalanine were used
to construct a standard curve to quantify unknown concentration samples.
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2.2.2

Liquid-Liquid Extraction
In the original pp JB2.274 system, liquid-liquid extraction was used to purify the

para-hydroxy benzoic acid. Because of this, this was the first method used for
purification of phenylalanine secreted into the media. Growth media was first cleared of
bacteria by centrifugation at 4,000 rpm for 10 minutes in a Beckman Avanti J-25
Centrifuge. The pH of the media was dropped to 2.0 using concentrated HCl. Aromatic
products were then mixed with a 1:0.5 ratio of clarified media to ethyl acetate and
thoroughly shaken to encourage mixing before separation in a separatory flask. The
upper (organic) layer was retained and the lower (aqueous) layer was extracted twice
more. The organic layers were combined and ethyl acetate was evaporated in a fume
hood.
2.3.2

HPLC Separation
Phenylalanine supernatant was first purified using a Hitachi LaChrom C18

column with an acetonitrile gradient. To determine the elution time of phenylalanine in
the method, samples were compared with a phenylalanine standard sample, consisting of
20 mM phenylalanine in minimal M9 media (Appendix E). Due to inefficient binding of
phenylalanine to the column leading to broad peak widths (Figure 2.9), a PRP1-C18
column was used.
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Figure 2.9 Separation of phenylalanine from M9 media after bacterial growth. Standard
phenylalanine in M9 sample (blue) compared with bacterial supernatant after 24 hours of
growth. Peaks representative of phenylalanine highlighted by a blue arrow.

With the PRP-1/C18 column, a better separation was achieved. The same acetonitrile
gradient method was used for elution.

2.2.4

UV Wavelength Scan
UV readings were used also to confirm the concentration of phenylalanine after

HPLC separation of the supernatant. Because these samples were very pure, a
characteristic shape of phenylalanine was observable in the UV wavelength. (Figure
2.10). This served as a secondary confirmation of the HPLC fractions that the
phenylalanine was present in the samples.
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Figure 2.10 Absorbance versus wavelength of a standard sample of 20 mM
phenylalanine (blue) and an HPLC purified fraction of recombinantly produced
phenylalanine (red).
2.2.5

1D Nuclear Magnetic Resonance
Correct () labeling pattern of recombinantly produced phenylalanine was

next confirmed. Small molecule NMR studies were performed on the purified,
evaporated phenylalanine products to determine the pattern and efficiency of labeling as
compared to commercially available unlabeled phenylalanine and uniformly 13C labeled
phenylalanine. Dried phenylalanine was resuspended in D2O and NMR spectra acquired
at 25 °C on a 500 MHz Varian Inova spectrometer equipped with room temperature
probe. One dimensional 1H spectra were acquired with a 7,000 Hz sweep width centered
at 6 ppm. Four thousand points were collected and 16 transients were averaged. The
recycle delay was 3 seconds (Figure 2.11).
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Figure 2.11 Standard 1H spectrum of phenylalanine with each of the protons
accounted for: β around 3 ppm, α at 4, and the aromatics just above 7. The peak at 4.7 is
water, the solvent.

A 13C spectrum was acquired with 12,000 Hz sweep width, centered at 70 ppm, 2k
points with 32 transients averaged. A 13C-HSQC (Figure 2.12) was acquired using the
same 1H and 13C parameters as previously described for the one dimensional
experiments. In the indirect dimension, 128 points (64 real + 64 imaginary) were
collected with 16 transients per increment.
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Figure 2.12 Standard 13C spectrum of fully labeled phenylalanine with carbons indicated
by Greek letters. Inset includes pattern specifically labeled phenylalanine, with the alpha,
gamma, and epsilon labeled residues in blue.

2.3

Recombinant Protein Production

2.3.1

Ubiquitin Expression and Purification
Ubiquitin mutant K48C in pET28b was transformed into chemically competent E.

coli strain BL21 (DE3). All cultures were grown at 37 C in shake flasks with 30 g/mL
Kanamycin unless otherwise noted. A single colony was grown in 3 mL of LB
overnight. After pelleting by centrifugation, the cells were resuspended in 30 mL
intermediate culture of unlabeled M9 media and grown for approximately 12 hours. The
intermediate culture was spun down, resuspended in 1 L of M9 minimal media, and
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grown to an OD600 of 0.8. Protein expression was initiated with addition of isopropyl αD-1-thiogalactopyranoside (IPTG) at 1 mM. Six hours after induction, cells were
harvested by centrifugation at 10,000 g for 10 minutes at 4 C and cell pellets stored at 80C. SDS-PAGE was used to quantify over-expression levels.
Pelleted cells were resuspended in 50 mM Tris-HCl, pH 8.0. Lysozyme was
added to 10 mg/mL followed by heating in a hot water bath at 65 C for 30 minutes.
MgCl2 was added to a final concentration of 5 mM and 0.8 units/mL DNase was added
before incubating at room temperature for 30 minutes. Cellular debris was removed by
centrifugation at 20,000 g for 15 minutes at 4 C. The supernatant was collected and
applied to a C4 HPLC column. Ubiquitin was eluted with an acetonitrile gradient and
fractions determined to contain the protein by SDS-PAGE (Appendix F) were pooled and
concentrated in 20 mM NaOAc, 20 µM NaN3, pH 5.0 for NMR analysis.

2.3.2

Pth1 Expression and Purification
E. coli Pth1 in pKQV4 vector was transformed into BL21 (DE3) pLysS cells

(Novagen) as described above. A single colony was grown in a starter culture consisting
of 3 mL LB and 100 g/mL carbenicillin for 8 hours. The cells were then spun down and
resuspended in 50 mL minimum M9 media with 100 μg/mL carbenicillin overnight. The
saturated culture was pelleted and cells resuspended in 1 L of M9 media, 100 g/mL
carbenicillin. For preparation of isotopically labeled protein, 15N ammonium chloride was
used as a nitrogen source. At an OD600 of 0.7, the culture was cooled to 30 °C on ice and
expression induced with 1 mM IPTG. To ensure sufficient aeration, no more than 500
mL of culture was grown in a 2 L flask. Cells were harvested after 6 hours and over46

expression verified by SDS-PAGE. Cells were pelleted and frozen at -80 °C for later
purification.
Purification of E. coli Pth1 consisted of metal chelation chromatography followed
by an optional size exclusion separation. A cell pellet from 1 L minimal M9 media was
resuspended in 30mL of 50 mM sodium phosphate, 300 mM sodium chloride, pH 7.4.
Fifteen milligrams of lysozyme resuspended in lysis buffer were added and the mixture
was incubated at room temperature for 30 minutes. The mixture was then sonicated
(50% power, 20 seconds sonication with 20 seconds rest on ice for total of 20 cycles) and
the insoluble material clarified by centrifugation (30 minutes, 25 kg).
E. coli Pth1 was purified from the soluble fraction on a 5 mL “HisTrap FF” nickel
column (GE Healthcare). The column was equilibrated with two column volumes of base
buffer: 50 mM sodium phosphate, 300 mM sodium chloride, pH 7.4. The cleared
supernatant was loaded and the column washed with base buffer plus 20 mM imidazole.
Pth1 was then eluted with 150 mM imidazole in base buffer. Fractions containing Pth1
were pooled and dialyzed against 50 mM sodium phosphate, 300 mM sodium chloride, 2
mM DTT, pH 7.4. After dialysis, purified protein was concentrated to 250 μM for
activity analysis. Protein concentration was determined by measuring UV absorbance at
280 nm using an extinction coefficient of 25440 M-1 cm-1calculated by the
ExPASyProtParam tool [33].

2.3.3

B. cereus Pth Cloning, Expression, and Purification
To compare variants of the peptidyl-tRNA hydrolase proteins, the B. cereus

variant was cloned and expressed to study the differences in inhibitory activity. B. cereus
was obtained from the American Tissue Type Collection (ATCC No. 14579). Genomic
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DNA was isolated using GeneJETGenomic DNA Purification kit
(Fermentas/ThermoFisher). The Pth1 gene was amplified from EcoRV digested B.
cereus genomic DNA with a PCR reaction containing 25 μL Emerald Mastermix
(TaKaRa), 2 μL parent DNA at a concentration of 119.72 μg/mL, 1 μL forward primer
and 1 μL reverse primer [100 mM], and 21 μL distilled deionized water to bring the
reaction mixture to 50 μL. The forward primer for B. cereus Pth1was designed to include
an EcoRI restriction enzyme site, start codon and hexa-histidine fusion tag for
purification (5’- CACGAATTCATGCAT CATCATCATCATCACA
GACGTAACCAAAATTGGT -3’). The reverse primer included a HindIII restriction
enzyme site (5’- GTGAAGCTTTCATTAACTATTGAAAGTATTCATGATT -3’). The
PCR reaction was carried out using the following cycling parameters: Step 1 at 95°C for
3 minutes; Step 2 at 95°C for 2 minutes; Step 3 at 56°C for 2 minutes; Step 4 at 72°C for
2 minutes; and Step 5 at 72°C for 7 minutes with steps 2 through 4 being repeated 24
times. Presence of amplified PCR product was detected by gel electrophoresis. The PCR
product was then purified from the reaction mixture using the GeneJET PCR Purification
Kit (Fermentas/ThermoFisher).
Purified PCR product and pKQV4 vector were digested with EcoRI and HindIII.
Digestion products were separated on 1% agarose gel and extracted. B. cereus Pth1 was
ligated into the pKQV4 vector and transformed into chemically competent JM109 cells
(Promega). Cells were plated on LB/carbenicillin plates, then grown overnight at 37 °C.
Single colonies were selected and grown to saturation in 3 mL of LB supplemented with
100 μg/mL carbenicillin. Plasmid DNA was isolated and sequenced to confirm the
integrity of B. cereus Pth1.
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2.3.4

Cdc42 Expression and Purification
Cdc42 was prepared as described previously [78-80]. Briefly, a single colony of

Cdc42 was grown overnight in 3 mL LB with 20 g/mL carbenicillin before resuspension
in 20 mL of M9 media for 8 hours. Saturated cells were pelleted by centrifugation and
resuspended in 500 mL 1 X M9 with 20 g/mL Carbenicillin. After growth to an OD600
of 0.8, protein expression was induced with 1 mM IPTG. After 6 hours, cells were
harvested, frozen, and expression verified by SDS-PAGE. Cdc42 was purified by metal
chelation chromatography. The eluted fusion protein was digested by thrombin and
applied to a Q-sepharose column. Cdc42 was eluted with a gradient of NaCl from 5 mM
to 1 M. Fractions containing Cdc42 were pooled and concentrated in 10 mM NaH2PO4, 1
mM EDTA, pH 7.0 for NMR analysis.

2.3.5

Sac7D Expression and Purification
Sac7d in pET-3b was transformed into chemically competent Rosetta (DE3)

pLysS cells. Growth and purification were based on previously established protocols
[79]. A single colony was used to inoculate 20 mL of LB and 24 L of 50 mg/mL
ampicillin in a 37 shake flask overnight. Two hundred milliliters of M9 media was
inoculated with 8 mL of the saturated LB culture along with 240 L of 50 mg/mL
ampicillin. When the OD600 reached 0.7, 50 mL of this culture was used to inoculate 2 L
of M9 along with 2.4 mL of 50 mg/mL ampicillin. When this culture reached an OD600
of 0.9, it was induced with 3.85 mL of 5 g/L IPTG. Protein expression proceeded in a
shake flask for 1 hour before being harvested by centrifugation at 10,000 g for 10 minutes
at 4 and cell pellets stored at -80C. Pelleted cells were resuspended in ice-cold lysis
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buffer containing 10 mM NaH2PO4, 1 mM EDTA, 0.5 mM PMSF, 150 L/100 mL 0.1%
Triton x-100, pH 7.0. The mixture was incubated at room temperature for 20 minutes
and then sonicated 6 times for 20 seconds at half maximal power with 20 second pauses
in between. The lysate was centrifuged at 20,000 g for 30 minutes at 4 C. For a heat
cut, the supernatant was warmed to 75 C for 15 minutes. A whitish precipitate was
removed by centrifugation at 20,000 g for 25 minutes at 4 C. The clarified supernatant
was separated and dialyzed against 2 L of 10 mM NaH2PO4, 1 mM EDTA, pH 7.0
overnight. Dialyzed protein was then loaded onto a 5 mL Sepharose SP ion exchange
column equilibrated with 10 mM NaH2PO4, pH 7.0. Sac7d was eluted with a linear
gradient from 0 to 1 M NaCl. Fractions containing Sac7d, determined by SDS-PAGE,
were pooled and dialyzed against water before concentration for NMR analysis.

2.4

Inhibitor Studies

2.4.1

Bacterial Inhibitor Toxicity
To assess the tolerance of BL21 cells with Ubiquitin vector to the shikimate

inhibitor glyphosate, toxicity tests were performed. A single colony of freshly
transformed Ubiquitin in BL21 cells was grown to saturation overnight in LB media in
the presence of 100 µg/mL carbenicillin. The following morning, 3 mL of this culture
was resuspended in 50 mL of minimal media, also with carbenicillin, and grown to an
optical density of 0.4. At this time, the culture was separated into seven 5 mL fractions.
Fifteen minutes prior to the optical density reaching 0.8, varying concentrations of
shikimate inhibitor were added, from 0 to 120 mL/L. An additional culture was grown in
which a supplementary cocktail of 20mM of each of the aromatic amino acids was fed.
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The OD600 was monitored over several hours to determine the toxicity level of the
inhibitor, as evidenced by a decline in growth.

2.4.2

Inhibitor Effects on Protein Expression
To determine what concentration of inhibitor effected protein expression,

expression studies were performed. Three milliliters of LB media with 100 µg/mL of
carbenicillin were inoculated with a scraping of frozen Ubiquitin/BL21 stock and grown
to saturation at 37 °C with shaking. At this point, this starter culture was spun down and
resuspended in 30 mL of minimal media, also with 100 µg/mL of carbenicillin overnight.
The following morning, 9 mL of this culture was spun down and resuspended in 70 mL
of minimal media with 100 µg/mL of carbenicillin. At an OD600 of 0.6, the culture was
separated into 9-5 mL cultures, and shikimate inhibitor was added at either 7 or 20 mL/L,
along with 50-400 mg/L of aromatic amino acid supplement. The cultures were induced
with 1 mM IPTG at OD600of 0.8, and cells were harvested 4 hours later. Protein
expression was observed using SDS-PAGE.

2.4.3

Inhibitor Recovery
Expression studies were performed to determine the optimal OD600of growth at

which to inhibit the cells. Inhibition with 20 mL/L of glyphosate was fed at initial culture
resuspension and several OD600 levels up to 0.8. The timing and concentration of amino
acid recovery (supplement of phenylalanine, tyrosine, and tryptophan to the culture
media in response to inhibition of shikimate pathway) was also determined. Amino acids
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were added at the initial culture resuspension time and at OD600 levels up to 0.8 or time of
induction and up to 2 hours after inhibition with glyphosate.

2.5

NMR Spectroscopy
For NMR studies, uniform 15N protein was produced (as described or mention

M9, M9+20). All data were collected at 25 °C using Varian Inova spectrometers
equipped with room temperature probes. For small molecule NMR, data was collected at
500MHz in 99% D2O. Protein NMR data including 15N-HSQC experiments were
collected at both 500 and 800 MHz in a buffer of 20 mM Bis-Tris, 50 mM NaCl, and 2
mM DTT, pH 7.4 for Pth1, and 20 mM NaOAc, 20 µM NaN3, pH 5.0 for Ubiquitin.
Typical data sets used the following parameters: 12 ppm sweep width in 1H, carrier on
water and 4.77 ppm, 32 ppm sweep width in 15N, carrier at 118 ppm, 96 indirect
increments, 16 transients, with a recycling delay of 1.5 seconds. Data in the form of a
.fid files were processed with nmrPipe [80] and visualized with Sparky [81](Appendix
C). Integrated peak volumes were compared after concentration normalization, and
comparative samples were always run consecutively to avoid any over time drift.

2.6

Labeling Method Development

2.6.1

Ubiquitin Reverse Labeling
To determine the percent labeling of phenylalanine within ubiquitin protein,

cultures were grown in the presence of 15NH4Cl and the phenylalanine residues were
selectively "unlabeled." Bacteria were grown in a fully labeled background and
supplemented with unlabeled phenylalanine. This means that if labeling were 100%
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successful, the phenylalanine residues would be invisible in an HSQC, while all other
peaks were of the same volume as a standard fully labeled spectrum.
The first reverse labeling study compared the mg/L of aromatic amino acid
supplement from 0 to 2 g/L to see if this made a difference on the labeling. A culture of
3 mL LB broth was inoculated with a scraping of Ubiquitin containing BL21 frozen cell
stock and kanamycin at 30 µg/mL. Upon saturation (about 6-8 hours growth), this
culture was spun down and resuspended in 80 mL of M9 minimal media (also in the
presence of kanamycin) overnight. The following morning, 80 mL of M9 was spun down
and resuspended into 750 mL of 15N M9 media. This culture was grown at 37 ° C with
shaking until it reached an OD600 of 0.4. At this point, the culture was separated into 6
125 mL flasks and supplemented with 20 mL/L of shikimate inhibitor as well as varying
concentrations of aromatic amino acids including: 0, 200, 500, 1000 and 2000 mg/L. An
additional sample at 500 mg/L was used with exclusively phenylalanine supplemented
instead of phenylalanine, tyrosine, and tryptophan. These cultures were induced with 1
mM IPTG at OD600 of 0.8, and harvested 4 hours later. Each culture was purified
separately and HSQC obtained to compare labeling.

2.6.2

Pth1 Reverse Labeling
To confirm the broad applicability of the method, we used the best conditions for

incorporation of the ubiquitin protein on the Pth1 (peptidyl-tRNA hydrolase) protein. An
advantage of the Pth1 protein is that it contains tryptophan residues, not present in
ubiquitin, to confirm the incorporation method is effective for each of the three aromatic
residues. For the growth, 3mL of Luria Broth, including 100 µg/mL carbenicillin were
inoculated with a frozen cell scraping of Pth1 H20R and grown for 6-8 hours at 37° C in
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a shaking incubator until saturated. One and one half milliliters of this culture were spun
down and resuspended into 50 mL M9 overnight before resuspending this intermediate
culture into 1L of M9 media. This culture was grown to an OD600 of 0.4 and inhibited
with 7 mL of shikimate inhibitor. One hour later, the culture was recovered with 500
mg/L each of phenylalanine, tyrosine, and tryptophan. The culture was induced with
1 mM IPTG at an OD600 of 0.6, at which time the temperature was dropped to 25° C for
expression overnight. Frozen pelleted cells were purified according to the procedure
mentioned above.

2.6.3

Sac7D Reverse Labeling
For Sac7d, FYW residue labeling of greater than 80% was achieved by

inhibiting with 20 ml/L of shikimate inhibitor at OD600 0.5, followed by a 30 minute
starvation period before supplementation with 500 mg/L F,Y, and W. These cells were
induced with 0.2 mM IPTG at OD600 1.0, and harvested 1 hour later.

2.6.4

Ubiquitin Forward Labeling
Forward labeling studies included growing bacteria in an unlabeled background

and introducing 15N and 13C labeled aromatics. For selective labeling of phenylalanine
residues in ubiquitin, mutant K48C in pET28b in BL21 (DE3) E. coli cells were grown
first in 3 mL of Luria Broth in the presence of 30 g/mL kanamycin for 7 hours until
saturated with shaking at 37 °C. One milliliter of this culture was centrifuged and
resuspended in 25 mL M9 media overnight. The following morning, this intermediate
culture was resuspended in 0.5 L of M9 media. This culture was grown to an OD600 of
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0.6, at which time it was spun down and resuspended in M9+20 Phe (Table 2.5) with 7
ml/L of shikimate inhibitor. Protein production was induced with 1 mM IPTG at an
OD600 of 0.8, and cells were harvested 4 hours later.

2.6.5

Pth1 Forward Labeling
For the forward labeling studies of Pth1, 15N phenylalanine, tyrosine, and

tryptophan were each separately incorporated into an unlabeled Pth1 H20R protein.
Three milliliters of Luria Broth in the presence of 100 µg/mL carbenicillin was
inoculated with a scraping of frozen Pth1 H20R and grown for 7 hours until saturated
while shaking at 37 °C. One milliliter of this culture was centrifuged and resuspended in
25 mL M9 media overnight. The following morning, this M9 intermediate culture was
resuspended in 0.5 L of M9 media. This culture was grown to an OD600 of 1.0, at which
time it was centrifuged and resuspended into 1 L of M9+20 (Aromatic) (Table 2.5) media
such that the final OD600 would be 0.5.

Table 2.5 M9 +20 Phe Recipe
1Liter M9 + 20 (Aromatic)
6.7 g
3g
0.5 g
0.04 g
0.3 g
0.3 g
0.15g
10mL
2 mL
10L

Na2HPO4
KH2PO4
NaCl
each of 4 nucleotides (A, T, C, G)
aspartic acid, glutamic acid, aromatics not labeled
15
N phenylalanine, tyrosine, or tryptophan
each of the remaining 16 amino acids
divalents
vitamin B
trace elements
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At this time, the culture was also supplemented with 7 mL of shikimate inhibitor.
This culture was grown to an OD600of 0.7, at which time it was induced with 1 mM IPTG
and the temperature dropped to 30 °C overnight before harvesting. The subsequent pellet
was frozen and purified according to the Pth1 purification procedure described above.

2.6.6

PSAL Phe Incorporation into Ubiquitin
Purified epsilon labeled phenylalanine obtained from HPLC purification was

evaporated to dryness, quantified using UV-spectrometry, and added to M9 +20 minimal
media at a concentration of 200 mg/L. From a fresh transformation of ubiquitin mutant
K48C in pET28b into BL21 cells, a single colony was grown in 3 mL of LB broth in the
presence of 30 µg/mL of Kanamycin. This culture was grown in a shake flask at 37° C
for approximately 6 hours, until saturated. At this time, 0.5 mL of the culture was
centrifuged and resuspended into 3 mL of M9 minimal media and grown at 37° C
overnight. The following morning, the 3 mL M9 culture was centrifuged and
resuspended into 85 mL of fresh M9 media. This culture was grown to an OD600
of 0.9 before being centrifuged and resuspended in M9+20 media including the 13C, 15N
epsilon labeled phenylalanine. Once resuspended, the OD600 was approximately 0.6. At
time of resuspension, 7 ml/L of commercially available shikimate inhibitor was also
added. This culture was grown to an OD600 of 0.8, at which time protein expression was
induced with 1 mM IPTG. Cells were harvested by centrifugation and pellets frozen at
-80°C until ready for purification. Protein expression was verified with SDS-PAGE, and
protein was purified as described above. Once purified, accuracy and fidelity of the
incorporated pattern was verified using 1D and 2D NMR spectroscopy.
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2.7

Pth1:peptidyl-tRNAComplex via Small Angle Neutron Scattering

2.7.1

Pth1:peptidyl-tRNA Complex Preparation
Small angle neutron scattering experiments have been performed on the E. coli

Pth1:peptidyl-tRNA complex. Catalytically inactive Pth1 H20R was grown in E. coli
BL21 cells in minimal media at 37 C to an OD600 of 0.7, at which point protein
production the temperature was dropped to 30 C and the culture was induced with 1
mM IPTG. Protein expression continued overnight, and was verified by SDS-PAGE.
Purification of Pth1 and peptidyl-tRNA was performed as previously described [68].
Pth1 H20R was complexed with bulk peptidyl-tRNA in a 1:1 molar ratio in buffer
containing 20 mM Bis-Tris, 50mM NaCl, and 2 mM DTT. To obtain Pth1 H20R and
tRNA complexes at varying D2O concentrations, six solutions of D2O were prepared:
0, 10, 18, 70, 85, and 100 % D2O. Purified Pth1 H20R and tRNA were put into
separate 1,000 MWCO dialysis bags and placed into the same D2O percentage buffer
(20 mM Bis-Tris, 50mM NaCl, and 2 mM DTT) to ensure that the D2O concentration
of each would be the same before they were complexed. The dialysis buffer was then
used as the blank sample for beam experiments to ensure that background subtraction
would be correct. Pth1 H20R was complexed with bulk peptidyl-tRNA in a 1:1 molar
ratio (~ 2 mg/mL) at each D2O percentage.
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2.7.2

SANS Data Collection and Analysis
Neutron scattering experiments were performed at the High Field Isotope Reactor

at Oak Ridge National Laboratories at beam CG-3, in the cold-guide hall. A volume of
200 µL of each sample were added to a 1 mm quartz "banjo" cell at room temperature at
a sample detector distance of 1.7 meters. Exposure times were from 60 minutes to 240
minutes, depending on the D2O concentration. Buffers for each of the concentrations
were also measured, along with empty cuvette and pure H20, D2O, as well as porasil B
standards for data reduction and background subtraction. Data were collected using a
phase contrast series with D2O concentrations of 0, 10, 18, 70, 85, and 100% in the
buffer, allowing for a more complete picture of the complex. Data were reduced and
analyzed in IGOR before using GNOM [82] to analyze the overall radius of gyration of
the complex using a Guinier approximation [83]. GNOM analysis was based on a
spherical model. Using the GNOM output as an upper limit for size, the scattering
density curves were input into MONSA [84], an ab initio modeling program. The data
were analyzed based on a zero symmetry model. The shape obtained from MONSA was
overlaid with the crystal structures of E. Coli Pth1 and tRNA using Chimera [85].
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CHAPTER III

RESULTS

3.1

Genetic Modifications
The original system used included JB161 cells designed to produce para-

hydroxybenzoic acid as the primary product [74]. The system also included a cloning
vector, (pJB2.274) engineered to have an enhanced aromatic amino acid biosynthesis
pathway and a secretase to secrete the products into the media (Figure 3.1).

Figure 3.1 The original system included genomic modifications for enhanced carbon flux,
as well as a vector with additional PHB producing and aromatic enhancing genes, and a
secretase to secrete the products into the media.

59

The initial glucose concentration was 15 g/L for this system in a fed batch glucose
fermenter feed. It was reported that the pJB2.274 vector in the JB 161 cells produced 4
g/L of phenylalanine as a byproduct of the para-hydroxybenzoic acid production which
corresponds to a 4% conversion of glucose to phenylalanine.
To produce phenylalanine, we first attempted to use the JB161 cells and
unmodified p JB2.274 vector. The JB161 cells include the following genes in the
genome: serA, aroA, aroL, aroC, aroB, trpC-E, trpR, tyrA and pheA (coding for
phosphoglycerate dehydrogenase, 5-enolpyruvylshikimate-3-phosphate synthetase,
shikimate kinase, chorismate synthase, 3-dehydroquinate synthase, indole-3glycerolphosphate synthetase/N-(5-phosphoribosyl) anthranilate isomerase, DNAbinding transcriptional repressor, chorismate mutase/prephenate dehydrogenase, and
chorismate mutase P/prephenate dehyratase, respectively. The vector map for the p JB p
JB2.274 vector is included in Figure 3.2.

E

K
aroF

(H)

K
pubiC

serA

tktA

(H)

E
Cm

R

P JB p JB2.274 (8.2
kb)
Figure 3.2 Vector map from the Frost lab. Restriction enzyme sites are abbreviated
as follows: E = EcoRI, K = KpnI, H = HindIII, parenthesis indicate site was removed.
Figure reproduced from [74].
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3.1.1

Sequencing the p JB2.274 Vector
Initially, the reported restriction sites were used to cut out the ubiC gene (coding

for chorismate-pyruvate lyase) to replace it with phenylalanine producing genes, but the
expected size of DNA fragments was not observed. Therefore, the pJB2.274 vector was
sequenced to determine the location of the ubiC gene and which restriction sites were
present that could be used to cut out the gene producing para-hydroxybenzoic acid and
replace it with phenylalanine producing genes. (Appendix G)

3.1.2

Addition of tyrB and aroC Genes

Once the correct sequence was determined, other aromatic producing genes could
be spliced into the vector in place of ubiC. The first genes identified to use in place of
the para-hydroxybenzoic acid were tyrB and aroC, coding for aminotransferase and
chorismate synthase, respectively [75, 76]. TyrB and aroC are found in the aromatic
amino acid biosynthesis pathway just after (tyrB) and just before (aroC) chorismate, the
last intermediates before phenylalanine production. This makes these genes excellent
targets for amplification of the last step in this pathway (phenylalanine) because
overproduction of these enzymes will increase the direction of this pathway through mass
action. These genes were amplified from pET-16 vector with Ampicillin resistance using
primers designed to include the restriction sites EcoRI on the forward primer and XbaI on
the reverse primer. Sequencing results showed that these were the restriction sites which
flank the ubiC gene (Figure 3.2). Initial attempts to cut the amplified band out of an
acrylamide gel and ligate it into a pET-28 vector failed. It was determined that the UV
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light box that was used to image the gels before cutting was taking too long to take a
picture and was damaging the DNA such that it could not be ligated back into the vector.
After this step was eliminated, ligations were successful. The purified DNA cut after the
PCR amplification was sequenced to confirm the fidelity of the sequence, and then cut
into a Pet-28 vector in place of the ubiC gene. After this sequence was also found to be
correct, the aroC or tyrB genes could be put into the p JB2.274 vector in the place of the
ubiC gene (Appendix H).

3.1.3

Phenylalanine production from tyrB and aroC
After the addition of tyrB and aroC, time growth studies were performed to

observe the change in aromatic production after the additions (Figure 3.3). Cells were
grown in minimal media for 48 hours and then the supernatant was diluted with water
and a UV wavelength scan from 240 to 315 nm was attained. The reduction in the
production of PHB observed by a maximum absorbance of 245 nm is apparent after the
removal of the ubiC gene and its replacement with aroC.

62

Absorbance (AU)

1.4
1.2
1
0.8
0.6
0.4
0.2
0

ubiC
tyrB

230

280
Wavelength (nanometers)

Figure 3.3 Wavelength scan of pJB2.274 vector with ubiC gene (blue) compared to
same vector with the ubiC gene replaced with tyrB vector (green.) The tyrB vector
clearly produces less para-hydroxy benzoic acid (absorbing at ~ 250 nm) but does not
produce more phenylalanine (absorbing at ~ 260 nm).

3.1.4

ydiB and aroK
Because there was only a marginal increase in aromatic production with the

addition of the aroC and tyrB genes individually, additional genes were added. Previous
results showed that combinations of aromatic amino acid biosynthesis pathway genes
dramatically increased production of aromatics by avoiding enzymatic bottlenecks [55].
The genes ydiB and aroK, coding for shikimate dehydrogenase and shikimate kinase,
were added at the ubiC gene at the 3’ end using restriction sites XbaI and XhoI
(Appendix I).
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The XhoI site was not originally in the vector, but was added using mutagenesis.
The mutation was an A to a G, and is indicated in the original sequence (Appendix G)
underlined. Due to difficulties in ligating the aroC gene into the pET-28 vector, a pprime cloning vector was used in its place for the intermediate cloning step of the aroK
and ydiB genes before being ligated back into the pJB2.274 vector. The p-prime vector
includes a 5’ and 3’ U overhang such that hybridization occurs from PCR products
directly into the vector without needing to cut the edges of the gene to be inserted or the
insertion vector. This way, if the restriction endonuclease site is too close to the edges of
the amplified gene for it to be properly inserted, a p-prime cloning vector can be used to
put the gene into this intermediate vector before cutting into the actual vector later. The
p-prime vector also includes a gene (lac-Z, coding for β- galactosidase) that causes
colonies produced to be blue in the presence of X-gal. If a gene is inserted into the
vector, the lac-Z is interrupted, causing the colonies produced to be white. This serves as
a selection tool after bacterial transformation in that only white colonies have an inserted
gene, and these are the only colonies that will be used.

3.1.5 Comparison of Genetic Variants
After confirmation of DNA fidelity using sequencing, the vectors containing these
genes were transformed into JB161 cells and grown over a period of days taking many
representative samples for time studies to determine the most efficient producers of
phenylalanine. Comparing only genetic variants with other growth conditions kept
constant, the most efficient producer of phenylalanine was determined to be the
combination of tyrB with aroK genes at 12-24 hours of growth (Figure 3.4).

64

1.2

ubiC
aroC

1

tyrB
aroC/aroK

0.8

aroC/ydiB
0.6

tyrB/aroK
tyrB/ydiB

0.4
0.2
0
230

250

270

290

310

Figure 3.4 Absorbance versus wavelength of genetic variants constructed in comparison
with the original p JB2.274 vector gene, ubiC.

3.2

Purification and Quantification of Phenylalanine

3.2.1

UV Quantification of Phenylalanine
Several methods were used to quantify the amount of phenylalanine produced.

During bacterial growth, visible absorbance was used as a measurement of phenylalanine
production. A sample of bacterial culture was collected and spun down to remove any
cell debris, and the supernatant was scanned from 220 to 340 nm. The absorbance at 260
nm was compared to a standard curve (Figure 3.5) to quantify the phenylalanine in the
sample. As this was a sample directly from bacterial culture, it is assumed that the
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concentration obtained from this method was artificially inflated due to other absorbing
compounds in the supernatant. Despite this limitation, an approximate upper limit of
concentration could be obtained.

Absorbance

0.8

0.4

0

240
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Figure 3.5 Standard phenylalanine (20 Mm) absorbance wavelength scan.
3.2.2

Liquid-Liquid Extraction
Once the culture growth was complete, an ethyl acetate extraction was used to

isolate the aromatic compounds from the culture media. The liquid-liquid extraction,
while very effective for extraction of para-hydroxy benzoic acid, proved very inefficient
for phenylalanine, forcing a new purification technique to be investigated (Figure 3.6).

66

1
0.9
0.8
0.7

Absorbance

initial
0.6

stage 1 lower

0.5

stage 2 lower

0.4

stage 3 lower

0.3
0.2
0.1
0
240

245

250

255

260

265

270

275

280

wavelength (nm)

Figure 3.6 Extraction Data from Phenylalanine standard sample. Initial is the absorbance
before extraction, Stages 1, 2, and 3 lower indicate the ethyl acetate layer in three
subsequent extraction stages.

3.2.3 HPLC Separation
For separation of phenylalanine from culture media, a PRP1-C18 HPLC column
(21.2 x 250 mm) was used. Room temperature phenylalanine eluted at 60% acetonitrile.
This column gave clean separation of phenylalanine from the media, and also offered a
means of quantification of the phenylalanine in the media (Figure 3.7). Supernatant
from tyrB/aroK variant was spun down, taken to pH 2.0 with concentrated HCl, and
filtered through a .22 micron filter before being loaded onto the column in 5 mL aliquots.
The flow rate was 3 mL/min, so additional aliquots were loaded after 1.7 minutes of run
time. An acetonitrile gradient from 0 to 90% was utilized and elongated at 50% to
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achieve cleaner separation of the phenylalanine peak.

Figure 3.7 Phenylalanine standard sample in blue (20 Mm phenylalanine resuspended
in minimal M9 media) and p JB2.274tryBaroK variant in red.

HPLC optimization variables included concentration of acetonitrile and length and
shape of the gradient (Figure 3.6), as well as pH of the loaded buffer, which was
optimized at pH 2.0. At pH 2.0, the phenylalanine had tighter binding to the column,
resulting in higher yields of purified product.

3.2.4

1D NMR Confirmation of Phe Product

A standard phenylalanine 1H spectrum was overlaid with the proton dimension of
a PSAL phenylalanine 13C HSQC spectrum as seen in Figure 3.8. The alpha residues are
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seen at 4 ppm, the beta at 3 ppm, and the aromatic residues just above 7 ppm. The signal
at 4.7 ppm is water, the solvent. The 1H proton spectrum of PSAL phenylalanine clearly
indicates that exclusively the alpha and epsilon carbons in phenylalanine are labeled.

Figure 3.8 Standard phenylalanine in black with PSAL phe offset slightly and
overlaid in blue. Only the alpha and epsilon protons are labeled. Inset shows standard
phenylalanine molecule.

Once the proton spectrum was confirmed, a carbon experiment also showed
exclusive labeling of the alpha, gamma, and epsilon carbons (Figure 3.8). This is
evidenced by the alpha peak at 58 ppm, epsilon at130 pppm, and the gamma at 138 ppm.
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None of the other carbon peaks show, indicating clean labeling of the alpha, epsilon, and
gamma residues only.

Figure 3.9 Carbon HSQC of PSAL phenylalanine showing only and carbons
labeled. Inset labels carbons within phenylalanine.

These results confirm the success of the genetic modification plan, as well as the
purification.
3.2.5

NMR Conclusions
PSAL phenylalanine can be produced and purified as evidenced by the NMR

spectra. The next hurdle is incorporating the product into recombinant protein with high
efficiency while preventing scrambling of the carbons to other amino acid residues. To

70

accomplish this, a shikimate inhibitor was introduced into the media for protein
expression along with the purified PSAL phenylalanine in order to prevent the cells from
producing their own phenylalanine from other metabolites.
3.3

Shikimate Inhibitor Studies
Simple addition of aromatics to the growth media led to significant isotope

scrambling and low efficiency of labeling. To eliminate the cells ability to make their
own phenylalanine, a shikimate inhibitor, glyphosate, was used. This 5enolpyruvylshikimate-3-phosphate synthase inhibitor, in the inexpensive and readily
available commercial form Round Up™, shuts down the central pathway of aromatic
metabolism such that instead of synthesizing their own amino acids, the cells are forced
to use amino acids supplemented to them in the media. This allows control over what
type of amino acids incorporate into recombinant protein. Concentration and timing of
inhibitor was optimized to achieve most efficient carbon labeling and efficiency.
Inhibitor was added at varying dilutions from 2 mL/L-80 mL/L [33] from initial growth
to point of induction. Time after inhibition to recovery was varied from 0 to 3 hours.
The timing and concentration of amino acids was also optimized from 0-2 g/L fed from
the point of inhibition to the point of induction. The cells were induced with IPTG from
0-2 mM, as well as addition of iron (II) and iron (III) sulfate to the growth media from 02 mM. Level of aeration was varied using differing flask to volume ratios as well as
baffled flasks, and type of media (standard M9 versus MOPS). Concentration of
antibiotics in the media was also optimized, experimenting from 0- 200 µg/mL.
Concentration of glucose or glycerol in the growth media was varied from 1 g/L to 32 g/L
and compared to the amount of final product to determine efficiency. Time of protein
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expression before harvesting, and OD600 of resuspension in labeled media after growth in
unlabeled media was also optimized (data not shown.)

3.3.1

Inhibitor Toxicity
To determine the concentration of inhibitor to choose for an individual bacterial

system, first an expression test was performed. This determined the amount of inhibitor
the cultures could handle. Toxicity tests revealed that between 60 and 90 mL/L of
shikimate inhibitor was enough to kill the BL21 cells with ubiquitin vector. Inhibition
was apparent as low as 20 mL/L (Figure 3.10).
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Figure 3.10 OD600 versus concentration of inhibitor at 3 (blue) and 15 hours (red.) At 3
hours, the BL21 cells tolerate as much as 60 mL /L of shikimate inhibitor without a major
reduction in cell density. The effect of the inhibitor can be seen in as little as 20 mL /L
after 15 hours.
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Inhibitor concentration tolerance varied with different strains of bacteria, with some
general trends. If the inhibitor was added too soon or at a higher concentration, the
culture did not survive. If the inhibitor was added too late or at too low a concentration,
it did not effectively inhibit shikimate synthesis, leading to an ineffective labeling
strategy. The speed by which the shikimate inhibitor lead to growth arrest was
proportional to the concentration added. Waiting for an hour after inhibition to recover
the cells allowed a “starvation period” when it is presumed that the cultures deplete most
of the available aromatic amino acids, stalling the growth rate (Figure 3.11).
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Figure 3.11 OD600 versus time for no inhibitor (grey), 20 ml/L inhibitor with 200
mg/L amino acid supplement (green), and 20 ml/L inhibitor with no supplement
(blue). Arrows indicate addition of inhibitor and addition of supplement,
respectively.
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If this starvation period is too long, the cells are permanently damaged such that
even viable cultures will likely be unable to produce protein. Feeding the inhibitor at a
later OD600 mitigates this issue. Aromatic amino acid supplementation after inhibition is
critical for cell viability and protein expression. If too low a concentration of aromatic
amino acids were added (less than 100 mg/L), cells were not viable and unable to
produce protein. If too much was added (1 g/L), severe scrambling of label was seen in
other residues, and if too high (4 g/L), protein expression was diminished. Using the
optimized method of inhibition at an OD600 of one half hour prior to induction time in
regular growth with optimized concentration of inhibitor followed by 1 hour of
starvation, 500 mg/L of each of the three amino acids as a supplement, and then normal
expression induction with IPTG gave the highest percent incorporation. Using this
combination of inhibitor and recovery, 70% labeling was achieved using ubiquitin in
BL21 cells, and 60% labeling was achieved for Pth1 in standard minimal M9 media.

3.3.2

Forward Labeling Optimization
Because each of the amino acids were present in the M9+20 media, shikimate

inhibition was better tolerated in this media. This was evidenced by a continuous growth
rate after the addition of inhibitor which was not seen in reverse labeling. The
concentration of inhibitor optimized in reverse labeling was the same concentration used
in forward labeling. The best labeling strategy included a combination of modified M9
(M9 +20), shikimate inhibitor glyphosate, and pushing back on the isotopic scrambling
by supplementing the media with the most prominent bleed-through residues. High
protein over-expression using this inhibition/recovery method resulted in protein
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expression of 80% of normal expression without inhibition with shikimate inhibitor.
High efficiency labeling with as little as 400 mg/L of FYW is possible. At 120 mL/L
shikimate inhibitor, even the presence of 20 mM of each aromatic amino acid was not
enough to rescue the cells. After toxicity tests, expression studies were performed to
determine if the shikimate inhibitor effected protein expression. From the inhibitor
concentration versus expression study (Figure 3.12), it appears that there was no real
difference in expression after the initial inhibition with recovery. Because of the ability
of the cells to tolerate 20 mL/L of shikimate inhibitor, this was the concentration used for
further incorporation studies.
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Figure 3.12 Expression gels of ubiquitin protein with 7mL/L (top) and 20 mL/L (bottom)
shikimate inhibitor. Levels of aromatic amino acid recovery are indicated by 0, 50, 100,
200, and 400 mL/L. Uninduced (-) versus induced (+) samples for each level are
included. Arrows indicate ubiquitin protein.
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3.3.3

Additional Variables for Incorporation
In addition to testing the level of inhibitor that would be tolerated, additional

expression studies determined the timing at which to add shikimate inhibitor and the
concentration and timing at which to feed the amino acid supplement to the culture. At
the same time that concentration of inhibitor was tested with expression, level of nutrients
in the media was also tested. This had no effect on expression or labeling. Because of
this, 1X M9 was the media nutrient concentration of choice as it was the most economical
(Figure 3.13). Inhibitor concentration above 20 mL/L had a severe negative effect on
protein expression, confirming this was the maximum level that could be used.
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Figure 3.13 1X (top) versus 2X (bottom) M9 Inhibition/Expression gels. Uninduced (-)
and Induced (+) gel samples with decreasing concentrations of shikimate inhibitor in
mL/L. Arrow indicates Ubiquitin protein.
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3.4

Protein Production

3.4.1

Ubiquitin Expression and Purification
Expression of Ubiquitin was confirmed with SDS-PAGE, as seen in Figure 3.12

above in the uninduced versus induced gels. After resuspension in lysis buffer, addition
of lysozyme, sonication, and heat cut, the clarified pellet was loaded onto a Hitachi C4
column with an acetonitrile gradient (See Figure 3.14).
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Figure 3.14 HPLC chromatogram of Ubiquitin C4 purification. Ubiquitin elution (black)
with acetonitrile gradient (gray). Highest peak of acetonitrile scaled to 100%

After HPLC, fractions containing protein were determined by SDS-PAGE (Figure 3.15).
Ubiquitin elutes after the acetonitrile gradient at approximately 50% acetonitrile.
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Figure 3.15 SDS-PAGE from Ubiquitin purification. MW indicates molecular weight
marker, T, S, P, and L indicate Total protein, S is soluble fraction, P is insoluble fraction,
and L is loaded. Numbers indicate fraction tube numbers at 1 mL /min. Brackets indicate
fractions pooled.

In the above example, fractions 44-57 were pooled and dialyzed against water and
sodium acetate before being concentrated to 250 µL for the NMR sample. An 15NHSQC of fully 15N labeled ubiquitin can be seen in Figure 3.16.
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Figure 3.16 1H-15N HSQC of ubiquitin, where each red dot indicates a residue within the
ubiquitin protein.

3.4.2

E. coli Pth1 H20R Expression and Purification
Conditions that yielded the most total soluble E. coli Pth1 H20R were the

following: growth of cells at 37 °C until OD600 of 0.7 when protein expression was
induced with 1 Mm IPTG at 30 °C for 16 hours. Over 12 mg of purified protein was
obtained from 1 liter of growth media (Figure 3.17).
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Figure 3.17 Expression gel of Pth1 H20R. Lane 1 is molecular weight marker, Lane 2 is
uninduced (-) and lane 3 is induced (+) with IPTG. PthH20R protein is indicated with
arrow.

Taking advantage of the N-terminal hexa-histidine tag, metal chelation
chromatography resulted in >90% pure protein by SDS-PAGE (Figure 3.17).
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Figure 3.18 SDS Gel from Nickel Affinity Column. T, S, and P indicate total,
soluble fraction, and pellet, respectively. Numbers indicate fraction number. In this
example, fractions 53-88 were pooled.

The two dimensional 1H-15N HSQC spectrum showed good dispersion in both
dimensions with minimal overlapping resonances, a sign of a well folded protein (Figure
3.19). Data were acquired from a 300 μM sample in 2 hours at 800 MHz using a room
temperature probe.
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Figure 3.19 1H-15N HSQC Spectrum of Pth1 H20R.

3.5

Aromatic Incorporation Studies

3.5.1

Optimization of Labeling in Ubiquitin
For development of a method of incorporation into recombinant protein, we first

used 15N protein instead of 13C. Using M9+20 media (media with each nucleotide and
amino acid added separately) did label phenylalanine within the protein, but there was
significant isotopic scrambling to other residues. While addition of the shikimate
inhibitor glyphosate reduced the isotopic scrambling, it was not eliminated. The best
incorporation strategy resulted from taking advantage of mass balance to push-back on
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the residues most scrambled to, including tyrosine, aspartic acid and glutamic acid. This
in combination with shikimate inhibition reduced the scrambling while at the same time
increasing the phenylalanine labeling to >95%. Following the optimized protocol
resulted in less than 20% decrease in protein expression compared to that without
inhibition in the same media. This was quantified using peak volume analysis to
determine the labeling percentage (Figure 3.20).
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Figure 3.20 Optimization of phenylalanine incorporation in Ubiquitin. Each peak
represents an amino acid in the backbone of Ubiquitin. Phenylalanine residues are in red,
tyrosine in blue. Panel (A) is fully labeled Ubiquitin. Panel (B) is M9+20 media. Panel
C includes inhibition with shikimate and (D) includes pushing back on metabolism with
addition of aspartic acid, glutamic acid, and tyrosine at 400 mg/L.

Bacterial cultures were grown to an OD600 of 0.6, roughly 30 minutes prior to the
ideal point of inducing recombinant protein production in this system. Duplicate125 mL
cultures were fed the shikimate inhibitor glyphosate at 7 mL/L. After one hour, cultures
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were supplemented with 200 mg/L of each of L-phenylalanine, L-tyrosine, and Ltryptophan. When reaching the optimal cell density, protein expression was induced with
IPTG and harvested after 6 hours. Many variables were optimized to achieve highest
possible phenylalanine incorporation (Table 3.1). Though the matrix of variables was too
large to test everything simultaneously, a linear approach of optimizing one variable at a
time was adopted. We did our best to do multi-parameter optimization or at least enough
to characterize the interdependence. In the end, the method we developed worked using
the minimum of phenylalanine, achieving high levels of incorporation and minimal
scrambling.

Table 3.1 Optimization Parameters for Recombinant Incorporation
Parameter
Timing of Inhibitor
Conc. Of Inhibitor
Time after inhibition to recovery
Timing of amino acid addition
Conc. of aromatic amino acids
Duration of induction
IPTG concentration
Iron (II) and Iron (III) chloride
Level of aeration
MOPS vs M9 media
Conc. Of antibiotics
Glucose/Glycerol Conc.

Variation
Best condition
Initial to Induction
30 min prior to induction
0-80 ml/L
7 ml/L
0-3 hours
1 hour
Initial growth to Induction
resuspension in M9
0-2 g/L
250 mg/L
2-12 hours
4 hours
0-2 mM
0 mM
0-10 mM
2 mM Iron (III)
1 X – 8 X volume
4 X volume
MOPS/M9
M9 media
0-200 µg/mL
100 μg/ml Amp, 15 μg/L Kan
1-32 g/L
1 g/L glycerol
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3.5.3

Aromatic Labeling of Pth1
Once the method for incorporation was optimized in the model protein ubiquitin,

the method was applied to a different system that had different protein solubility,
aromatic content, and size to test whether the method was robust enough to be applicable
to a variety of recombinant systems.
Using the method optimized for ubiquitin, phenylalanine, tyrosine, and tryptophan
were each incorporated separately into PthH20R protein with high (>95%) efficiency and
less than 5% bleed through to other residues (See Figure 3.21).

Phe Labeling

TyrLabeling

Trp Labeling
Phenylalanine
Tyrosine
Tryptophan

Figure 3.21 Optimization of incorporation of aromatic amino acids into peptidyltRNAhydrolase. Phenylalanine residues are in red, tyrosine in blue, and tryptophan in
green. Black residues indicate bleed-through, grey are noise or unassigned peaks.
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3.5.4

Incorporation of PSAL Phe into Ubiquitin
With the recombinant PSAL phenylalanine and the method for incorporation into

ubiquitin both optimized, it was time to put these two pieces together for PSAL
phenylalanine incorporation into ubiquitin. Using the labeling strategy, ubiquitin was
recombinantly produced with PSAL phenylalanine labeling. A high degree of 13C
incorporation (>95%) was observed at the C, C and C positions as expected for the
two phenylalanine residues of ubiquitin (Figure 3.22). Line broadening as a result of
carbon-carbon coupling is not observed for the PSAL phenylalanine sample, even in nonconstant time data. Thus PSAL phenylalanine labeling removes the necessity of constant
time carbon chemical shift labeling, benefitting mid-size (20 kDa) and larger
macromolecular systems by simplifying spectra.

Figure 3.23 2D HSQC of phenylalanine incorporated into Ubiquitin. Left panel –
uniformly labeled phenylalanine in ubiquitin, Right – epsilon labeled phenylalanine
incorporated into ubiquitin.
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Now that an incorporation method was optimized for ubiquitin protein and applied to the
pth1 protein, low resolution structural studies were needed to confirm that the
phenylalanine residues present in the pth1: peptidyl-tRNA complex could be used for
high resolution structural studies.

3.6

Small Angle Neutron Scattering

3.6.1

Scattering Intensity Curves
SANS data were collected from samples of catalytically inactive

Pth1H20R:peptidyl-tRNA complex in buffer at six different H2O:D2O ratios, with the
highest scattering obtained from the sample with 100% D2O (See Figure 3.23).

Figure 3.23 Scattering density of varied percentages of D2O.
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The scattering density curve was converted into intensity versus Q using IGOR [87].
This produced a curve as in Figure 3.24, showing the intensity versus Q of each of the 6
D2O concentrations.

Figure 3.24 Scattering curves for Pth1H20R:peptidyl-tRNA complex from contrast series
measurements taken at buffer D2O concentrations of 0, 10, 18, 70, 85, and 100%.

3.6.2

GNOM for Rg
Scattering intensity curves, processed using IGOR were then input into GNOM

[82] for Rg values. The average radius of gyration, Rg, was 63 ± 4 Å from Guinier
analysis of the 100% D2O sample, in agreement with dynamic light scattering estimates
of 65 ± 7 Å. For illustration, the distribution of distance pairs resulting from SANS data
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collected at 100% D2O is shown in Figure 3.25, showing an Rg of approximately 66 Å, in
agreement with predictions based on studies of proposed peptide and tRNA binding
regions [72]. This figure also gives a Dmax of ~230 Å, which was used as an upper limit
in MONSA modeling.

Figure 3.25 Pairwise distance distribution function of scattering data from
complex in 100% D2O generated in GNOM [82].
During the processing stages of GNOM, intermediate data are obtained that indicate
correctness by a characteristic curvature (See figure 3.26).
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Figure 3.26 Intermediate step of GNOM showing a positive result of fitting.

3.6.3

MONSA Modeling
Using the Rg value as an upper limit on the size of the search space, the overall

shape of the Pth1H20R:peptidyl-tRNA complex was solved. Modeling results are shown
in Figure 3.27 with atomic coordinates from E. coli Pth1 (PDBID: 2PTH) and tRNAPhe
(PDBID: 1EHZ) modeled in. The shape of the envelope of the complex suggests the
location of the tRNA portion of the substrate and that of Pth1. Using available
information on the location of the active site residues [64, 66] and the proposed peptide
binding channel [88] for Pth1 with the structure of the enzyme:TC loop complex [89],
Pth1 and tRNA were successfully modeled into SANS envelope. The high resolution
coordinates of E. coli Pth1 (2PTH) were fitted into the low resolution SANS model
restricting the search to the part of the model that was not filled by the tRNA density
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using SUPCOMB. The normalized spatial discrepancy (NSD) value determined by
SUPCOMB was 0.54, indicating a good fit between the two volumes (i.e. NSD below
1.0.) [90]. Pth1 was oriented such that the positive patch and catalytic His20 residue
were near the tRNA 3’ terminus. The high heterogeneity of the substrate resulted in a
shape reflecting the various peptidyl-tRNA species and therefore, fitting the tRNA
portion in the bead model has not been as straight forward as that of Pth1. In the end, the
rigid tRNAPhe crystal structure was positioned manually leaving some unaccounted
volume in the anticodon region. Variation in this region comes from plasticity of the
tRNA molecule as a whole [91], mobility in the anticodon region [92], and heterogeneity
of the peptidyl-tRNA used for data collection.

94

Figure 3.27 Model of Pth1:peptidyl-tRNA Complex. The overall shape of the
Pth1H20R:peptidyl-tRNA complex is shown in gold spheres. E. coli Pth1
(PDBID: 2PTH) and tRNAPhe (PDBID:1EHZ) were fit into the mass density.
Pictured in the inset (lower right) are the individual components: tRNAPhe in
blue, Pth1 in red, and the calculated shape in gold spheres.

95

CHAPTER 4

DISCUSSION
4.1

PSAL Production
The production of PSAL phenylalanine was optimized to maximally convert

glycerol to phenylalanine. Other methods have used high glucose concentrations to
produce aromatic amino acids [49 51, 93-95]. Regrettably glucose with the appropriate
13

C labeling to achieve the same level of isotope incorporation as glycerol is not currently

available. There is also significant concern about isotope scrambling with such high
levels of carbon source and aromatic amino acid product. Regardless, it turns out using
glycerol as the sole carbon source is more efficient in our system. That is, more
phenylalanine is produced per gram of glycerol than glucose. In fact, reducing the
starting concentration of glycerol resulted in more efficient conversion (Table 4.1) and
decreased 13C scrambling. Thus glycerol was used as a carbon source. Additionally, an
insignificant increase in production of phenylalanine from increased aeration in
combination with decreasing returns on glycerol indicate that batch-fed fermentation
would not likely benefit this system.

Table 4.1 Carbon Efficiency (1 Liter cultures)
glycerol
(g/L)
1
2
3
4

unpurified
phe (mg)
377
580
592
698

% carbon
conversion
37
29
20
17
96

In sum, 377 milligrams of phenylalanine could be produced per liter of culture
starting with 1 g/L of glycerol, a 37% conversion of carbon. Isotope incorporation was
over 95% at the sites desired quantified by peak volume analysis. No 13C scrambling was
observed and optional 15N incorporation was also nearly complete by the substitution of
15

N ammonium chloride for the natural abundant version in the final production media.

4.2

Isotopic Labeling and Inhibitor Addition
Reverse labeling or “selective un-labeling” was the first method attempted for

isotopic incorporation. This method involves selectively un-labeling specific amino acid
residues against a fully labeled 13C, 15N background [96]. More specifically, labeling was
accomplished by supplementing 500 mg/L unlabeled phenylalanine, F; tyrosine, Y; and
tryptophan, W; to uniformly 15N labeled minimal M9 media. Timing of addition was
optimized, but this method yielded poor labeling results with significant isotopic
scrambling. Forward or traditional labeling using M9+20 (minimal media with each of
the four nucleotides and each of the 20 amino acids added separately instead of NH4Cl as
the nitrogen source) also resulted in isotopic scrambling. It was not possible to obtain
higher than 70% aromatic incorporation when simply supplementing minimal media with
aromatic amino acids (FYW), even at a concentration of 2 g/L phenylalanine, 500 mg/L
tyrosine and 500 mg/L tryptophan. Modified M9 in which no nitrogen source (NH4Cl) is
added but 200 mg/L of all 20 amino acids and 40 mg/L of all 4 dNTPs was added only
marginally improved labeling (20% increase) [25]. However the minimal M9+20 media
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alone lead to significant isotope scrambling. In order to improve labeling efficiency, the
shikimate inhibitor glyphosate was added [86].
Glyphosate was added to the growth media to shut down the synthesis of aromatic
amino acids such that bacteria are forced to take up supplemented aromatic amino acids
[33]. The shikimate inhibitor Round-Up was added at 7 ml/L approximately one hour
prior to induction with IPTG. Timing of inhibitor and recovery is critical to allow
sufficient time to deplete aromatic stores without permanently damaging the cells.
Feeding inhibitor at an OD approximately one hour prior to induction (0.5-0.6) optimized
labeling. A longer doubling time correlates with less inhibitor tolerance. Similarly,
faster growing cells necessitate a higher concentration of inhibitor. When determining
the amount of inhibitor to add, expression studies are a helpful diagnostic. Some
concentrations of inhibitor were low enough that cells were able to recover, meaning they
began growing again after supplementation with aromatic amino acids, but did not
express recombinant protein. High levels of protein over-expression were still possible
using this inhibition/recovery method. If the inhibitor was added too soon or at a higher
concentration, the culture did not survive. If the inhibitor was added too late or at too
low a concentration, it did not effectively inhibit the shikimate pathway, leading to an
ineffective labeling strategy. The speed by which the shikimate inhibitor led to growth
arrest was proportional to the concentration added, meaning a higher inhibitor
concentration lead to a faster growth arrest. Addition of shikimate inhibitor halted
growth of each culture within 15 minutes of addition. Cultures were able to recover
within 30 minutes of this inhibition to a normal growth rate when supplemented with
aromatic amino acids phenylalanine, tyrosine, and tryptophan. While the inhibitor
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addition significantly improved labeling efficiency, further optimization was desired.
The timing and concentration of amino acid recovery was also critical to proper labeling.
Cultures were fed inhibitor at varying concentrations dependent on their doubling time,
and then fed each of three aromatic amino acids, phenylalanine, tyrosine, and tryptophan
after 60 minutes of starved inhibition, as the cells depleted the available aromatics and
growth rate stalled. Without the addition of aromatic amino acids, protein expression and
growth was arrested. A decline in growth rate could be observed with as little as 2 ml/L
of inhibitor, and growth could not be recovered if inhibitor concentration was over 30
ml/L. Too much amino acid recovery in the form of supplementing with labeled
phenylalanine is not only costly ($375 per gram), but at a concentration above 2 grams
per liter the cell growth is negatively affected. The best overall labeling strategy was
achieved using a combination of M9+20, glyphosate, and addition of the amino acids that
were the most often bleed-through residues, that is, the residues that were undesirably
labeled with 15N when only phenylalanine was intended to be labeled (aspartic acid,
glutamic acid, and tyrosine). Cultures were grown to an OD600 of 0.8 in standard
minimal media before being pelleted and resuspended in 1.5 x volume of M9+20 media
with 15N Phe instead of standard Phe in the media. This resulted in an OD600 around 0.6,
which was approximately 1 hour prior to standard induction (OD600 of 0.8). Nucleotides
were added to media at 40 mg/L and standard amino acids were added at 200 mg/L.

15

N

phenylalanine, tyrosine, glutamic acid and aspartic acid were all added at 400 mg/L.
Phenylalanine was added in excess increase the labeling percentage, while tyrosine,
glutamic acid and aspartic acid were added to “push back” metabolically on the isotopic
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scrambling. This method resulted in >95% labeling of the phenylalanine residues with
less than 10% labeling of any other residue.
By following the guidelines established herein, high efficiency labeling with as
little as 400 mg/L of phenylalanine is possible. Two proteins varying in size and
aromatic content were used to show diversity in testing the labeling incorporation
techniques for development of a widely applicable method for incorporation of aromatic
amino acids into a recombinant protein with ease and high efficiency. With the reported
production of PSAL phenylalanine, this equates to a means of generating specifically
labeled protein with a cost on the same order as ILV methyl labeling ($150 per liter of
recombinant protein incorporation media).
This method is beneficial as a standalone method, but could be especially useful
when used in conjunction with perdeuteration, reducing 13C and 15N relaxation rates.
Perdeuteration in combination with labeling every other carbon will eliminate carbon Jcouplings, allowing for a strong NMR signal. Future studies will utilize guidelines
provided herein to incorporate aromatic amino acids into a variety of recombinant
proteins for macromolecular complex studies, including binding and structure
determination. Labeling one, two, or all three aromatic amino acids can be
accomplished without the use of transamination resistant cells or utilizing cell free
systems.

4.3

SANS Model
The overall shape of the Pth1: peptidyl-tRNA complex shows an extended shape

with minimal interaction between the tRNA and Pth1. This is somewhat different from
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the interaction between Pth1 and the TC loop of tRNA observed in a high resolution
crystal structure [89]. This may in part be due to the presence of an additional base, G-1,
in the TC structure that was necessary for crystallization. The differences might also be
the result of crystallization with the X-ray structure being forced into a low-population
state from crystal packing. Also the lack of peptide moiety on the tRNA may be a
contributing factor. In the MONSA model, the CCA terminus appears to be positioned
near the catalytic residue histidine 20, a requirement for substrate cleavage. The above
model also upholds finding that the D arm, anticodon arm and variable loop do not exist
in a location where they interact with Pth1. In the SANS model presented here, a
catalytically inactive Pth1 mutant (that still binds the substrate) was used. Thus the
enzymatic reaction did not occur but the tRNA portion of the substrate dissociated from
its original binding site. The dissociation might actually serve a functional purpose that
is to facilitate accommodation of the peptide in the peptide binding channel without
constraints imposed by tRNA binding to Pth1. On the other hand, a considerable strain
from bending the acceptor stem to fit the peptide component into the Pth1 peptide
recognition channel might aid in cleavage of the tRNA-peptide ester bond. Further
studies will be necessary to fully elucidate the intermediate steps.

4.4

Future Work

4.4.1

Additional Labeling Patterns
To achieve diversity within the pattern of labeling of phenylalanine, alternative

starting materials will be used. For example, to label the zeta position instead of the
epsilon position, 1-13C-Acetate could be used as the starting carbon source. Varied
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starting materials will be used as carbon sources and labeling patterns will be validated
using NMR spectroscopy.

4.4.2

Additional amino acids
In addition to varying the phenylalanine patterns, additional genetic modifications

will be performed to modify the phenylalanine producing system to produce both tyrosine
and tryptophan. Once these amino acids are produced and verified using NMR,
additional labeling patterns will be incorporated into these systems as well. A
combination of several aromatic amino acids with varied labeling patterns will provide a
multitude of options for pattern specific isotope incorporation into a recombinant system.

4.4.3

Scytovirin as a Future Application
Scytovirin is a 95 amino acid residue protein consisting of two almost identical

domains. This protein binds carbohydrates and has been shown to inhibit the interaction
of HIV virus with GP41, GP 160, and GP120 glycoproteins of T-cells [97]. While the
NMR structure of scytovirin has been solved, the exact mechanism of interaction with the
glycoproteins of HIV infected cells is unknown. Because this protein has no isoleucine,
leucine, or valine residues, ILV labeling is not helpful. This protein in complex with
GP41, GP160, or GP120 could elucidate information on the mechanism of inhibition,
leading to more effective anti-HIV therapeutics. Scytovirin has two phenylalanine
residues and two tryptophan residues that could be pattern specifically isotopically
labeled to reduce the size of the overall complex such that macromolecular structural
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interactions could be deduced. This is one of many possible future applications of pattern
specific, isotopically labeled aromatic amino acids.
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CHAPTER 5
Conclusions

Pattern specific isotopically labeled aromatic amino acids are economical to produce
and incorporate into a variety of recombinant bacterial systems and can be used to
elucidate structures and mechanisms of previously unknown macromolecular complexes.
Labeling of every other carbon in the aromatic ring of phenylalanine simplifies the NMR
spectra of both small molecule and protein samples, avoiding a J-coupling and reducing
signal noise due to every other carbon being labeled. Incorporation of PSAL
phenylalanine into recombinant proteins has also been optimized by taking advantage of
metabolic pathways. Modifications to the carbon metabolism by careful attention to
enzymatic bottlenecks and feedback inhibition results in a high efficiency production of
pattern specifically labeled phenylalanine that can be effectively incorporated into a
recombinant protein.
Though the Pth1: peptidyl-tRNA complex resists high resolution characterization,
future studies show promise. SANS data can be incorporated into solution structure
refinement by utilizing NOEs to solve the short-range interactions and the SANS data for
the shape. This has been particularly helpful for RNA complexes [98, 99]. Considerable
progress has been made in combining tRNA and peptides [100, 101], though scale up has
been problematic and/or expensive. Continued efforts will help understand the intricate
workings of Pth1 enzymes and hopefully fulfill their pharmacological potential.
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APPENDICES
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Appendix A Small Angle Neutron Scattering
A.1

Background
Small angle neutron scattering (SANS) measurements have begun to play a vital

role in structural and molecular biology, specifically macromolecular interactions such as
protein: protein, protein: DNA, and protein aggregation studies. One major advantage of
small angle neutron scattering is the ability to take advantage of phase contrast.
Biological species have characteristic scattering densities based upon their atomic
composition (See Figure A.1).

Figure A.1 Scattering densities vary with atomic composition. Figure taken from
[102].
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Figure A.2 Differences in scattering density of Pth1: peptidyl-tRNA hydrolase in
complex with tRNA.

This can be utilized by combining species with different D2O concentrations, by
studying a protonated species bound to a deuterated species, or by studying the natural
scattering density differences between types of compounds such as proteins versus
nucleic acids (See Figure A.2).
Because these studies can be performed in solution, it is not necessary to crystallize
the protein for the system to be studied. Scattering measurements can define the
maximum radius of a sample, or the Dmax [103]. These measurements can be combined
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with ab initio modeling programs such as MONSA [84] to solve the overall shape of a
complex. Small angle neutron scattering can be especially useful when a complex is too
large for NMR studies and cannot be crystallized, as is the case with the Pth1: peptidyltRNA complex. SANS data can be incorporated into structure refinement by utilizing
NOEs to solve the short-range interactions and the SANS data for the shape. This can be
particularly helpful for RNA complexes [98, 99].
A.2

Small Angle Neutron Scattering Sources
Neutrons can be generated in one of two ways: Fission and Spallation.

Fission uses a nuclear reactor to produce neutrons, while spallation utilizes a linear
accelerator for bombardment of heavy elements with protons to generate neutrons
[104] (Figure A.3).
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Figure A.3 Upper: Fission reaction, Lower: Spallation Source using proton
accelerator

In a reactor source, Uranium 256 is hit by a neutron and it splits into two
smaller atoms. Heat energy and gamma rays area released, as well as several neutrons
in this reaction. One of the neutrons can continue the chain reaction. The other
neutrons can be collected and collimated for research use or can be absorbed by a
neutron buffer such as beryllium. The energy produced by this reaction is more than
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three million times the energy produced by the same amount of coal burning. To
moderate the production of neutrons and energy, a liquid coolant (usually water) is
flowed continuously around the reactor core. Without moderation, the reaction could
proceed too quickly, resulting in a nuclear meltdown [105].
In a spallation source, protons are accelerated to greater than 90% the speed of
light in a linear accelerator before hitting a heavy metal target, such as mercury.
When protons hit the target, neutrons are “spalled” out, and can then be moderated
(with deuterium) and collimated to beam lines [106].
A.3

Neutron Scattering applications
Both types of instruments are only found at large facilities and should be used

only when other options are not feasible. Neutrons have a wavelength similar to
atomic distances, making them useful for studying biological molecules. Neutron
scattering is an elastic process, thus not damaging the sample [107]. The energy is not
measured; rather a detector simply counts the number and intensity of the scattered
neutrons. This is an advantage over crystallographic methods, in which the sample is
destroyed. In x-ray crystallography, inelastic scattering is used. This is a process in
which the kinetic energy of an incident particle is not conserved. Neutrons are
penetrative to matter, allowing large and complex samples to be studied thoroughly
[104]. Varied neutron sources will have different flux () of neutrons. Flux is
determined by the number of neutrons per second per area, and is units of # neutrons·
cm-2· sec -1. Fission reactors tend to have greater flux than pulsed spallation sources,
resulting in a stronger signal. The scattering intensity is dependent upon the
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molecular makeup of the sample. Scattering intensity, Q, is the measured output of
the beam, and is dependent on the wavelength of the incident neutrons, λ, and the
angle of scattering, θ. Scattering intensity is defined by the equation in figure A.4.

Figure A.4 Scattering intensity vector, Q

The measured scattering intensity can also be expressed as a function of the flux (IF),
solid angle (Ω°), detector efficiency (), sample transmission (T), and the differential
𝑑𝜎

cross section 𝑑𝛺 (Equation 1). Including these variables in calculations increases
accuracy of the measurements.
𝑑𝜎

Equation 1: 𝑄 = IF · Ω° · · T · 𝑑𝛺
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Appendix B – Crystallography

For more than 50 years, crystallography has been used by molecular biologists to
deduce structural information of proteins and macromolecular complexes [108].
Myoglobin was the first protein crystal structure to be solved in 1958 [109]. Since this
time, significant advances in the technique have been developed, including advances in
X-ray sources, mounting techniques, screening kits, data collection tools, and computer
software [110, 111]. Synchrotron radiation was an especially valuable advancement in
the technique, allowing for angstrom resolution of structures to be elucidated [112]. Xray crystallography is now a rapid and precise technique for obtaining the structure of
single crystals of proteins [113].
X-rays are excellent probes for atomic structures because the wavelength of an xray is on the order of the size of an atom [112]. The first step in protein crystallography
is to purify the protein of interest using standard biochemical methods. Next, one must
crystallize the protein. Each of these steps may require a great deal of trial and error and
optimization steps. Once the crystal is obtained, an x-ray diffraction is measured as spots
of varying intensities. The final step is to determine the phase and produce an image of
the protein based on diffraction spot intensity measurements.
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Appendix C NMRPipe Data Processing

Once .fid files are obtained from an NMR spectrometer, they are transferred to a
processing computer and located using command-line prompts. The terminal must be
opened to process the files. Once in the terminal, the command “cd” (change directory)
lists the folders available. Double-clicking on a selection of folder after typing “cd” will
open that folder. Once the .fid that needs to be processed is located, double-clicking the
file will highlight it, and clicking the middle mouse button will paste it into the command
line. Once the .fid files have been selected, typing “Varian” into the command line
brings up the program NMRPipe (See Figure C.1).

Figure C.1 Interface for NMRPipe.

Once in NMRPipe, clicking “Read Parameters” highlights three fields: Center Position
PPM (x and y axes), and Observe Freq MHz in the y-axis. (See Figure C.2). For a
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standard 15N sample, “Complex” under Acquisition mode in the y-axis is changed to
“Rance-Kay,” and the “Observe Freq MHz” is changed to ~ 200 for 15N samples. Once
these changes are made, highlighting in the boxes is removed automatically by the
program.

Figure C.2 Parameters highlighted in NMRPipe after reading in the .fid data

Once these changes are made, clicking “Execute Script” runs the program, and “Save
Script” saves the program. A confirmation pops up to confirm that the fid.com has been
saved. Now “Quit” can be selected to go back from NMRPipe to the terminal. Back in
the terminal, “NMRDraw” opens this program. In NMRDraw, right-clicking under
“File,” and then “Select File” will pull up “test.fid” (Figure C.3). This will be the .fid
that was just processed in NMRPipe. Clicking “Read/Draw” prompts the file to become

114

visible on the screen (Figure C.4). After the spectrum can be seen, clicking “Done” will
remove the loading panel.

Figure C.3 Selection panel for .fid files
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Figure C.4 Blue lines in the spectrum indicate data has been uploaded.
To begin processing the data, typing “h” anywhere in the grid space brings a horizontal
line into view, and a squiggly line at the bottom of the screen (Figure C.5).
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Figure C.5 NMRPipe data processing after typing “h” and observing a line.

Clicking the horizontal line in the middle of the screen and dragging it down to a yposition of 1 is the first step. Under “Proc” tab, (right click), “auto process 1D” is
selected, as well as “On” next to “Phasing.” Now the PO toggle on the upper left can be
adjusted until the base line of the spectra becomes flat (Figure C.6). When this is
achieved, the value next to “PO:” will need to be entered back into the terminal.
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Figure C.6 Adjusting the baseline to as flat as possible before returning to the terminal.

Selecting “Quit the Program” from the File menu returns the user to the terminal. Back
in the command line, “vi xy.com” brings up the parameters of the .fid (See Figure C.7).
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Figure C.7 Parameters of the .fid that can be modified. (In this example, the value
currently is -15.2 for Po)

The line after “nmrPipe –fn PS –Po” should be changed to the p0 value determined in
NMRPipe to have the flattest baseline. Once the baseline is changed, typing “:”
anywhere in the open window will bring the cursor to the bottom of the screen such that
the data can be saved by typing “wq” and enter. Back in the command line, typing “./
xy.com” will reload the file with the modified baseline. To return to NMRDraw for peak
picking, “nmrDraw” can now be typed into the command line. Now in addition to the
“test.fid” file, there is an “xy.ft2” file. Clicking this file followed by “Read/Draw” opens
up the HSQC (Figure C.8). If the peaks are well resolved, the data processing is
complete. If the peaks look stretched out or overlapping, further modifications to the .fid
are necessary.
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Figure C.8 HSQC in NMRDraw of Ubiquitin protein.

If the spectra need to be processed into an image file, this can be done with the
program “Sparky.” Peak volumes are integrated and compared to a standard volume
HSQC to determine relative percent labeling.
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APPENDIX D DNA Gels

Electrophoresis (DNA gel)
1% agarose gel
Agarose

0.35 g

1x TAE buffer

35 mL

Microwave 45 seconds

EtBr

12 mL

Running Buffer
1x TAE buffer
10 mL 50x TAE
490 mL dH2O

All DNA gel electrophoresis were conducted using FisherBiotechTM FB300
Electrophoresis Power Supply.
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APPENDIX E Standard Minimal Media (M9)

2x M9 2x Glucose 1 L
13.5 grams
6 grams
1 gram
8 grams
2 grams

Na2HPO4
KH2PO4
NaCl
Dextrose
NH4Cl

10 mL
2 mL
10 mL

Divalents
Vitamin B
Trace elements
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APPENDIX F SDS-PAGE

Gel Recipe
12% Resolving gel
H2 O
2 M Tris-HCl, pH 8.8
20% SDS
Acrylamide/Bis-acrylamide 30%/0.8%
10% ammonium persulfate (APS)
TEMED

2.4 mL
1.1 mL
37.5 mL
2.4 mL
40 mL
14 mL

4% Stacking gel
H2 O
0.5 M Tris-HCl, pH 6.8
20% SDS
Acrylamide/Bis-acrylamide 30%/0.8%
10% ammonium persulfate (APS)
TEMED

1.8 mL
0.75 mL
15 mL
0.40 mL
22 mL
5 mL

Loading buffer (2x)
H2 O
0.5 M Tris-HCl, pH 6.8
Glycerol
20% SDS
BME
bromophenol blue

10.4 mL
1.2 mL
1.9 mL
1.0 mL
0.5 mL
1% (pinch)

Running Buffer (10x)
Tris Base
Glycine
SDS
H2 O

60 g
280 g
8g
fill to 2 L

Staining Solution
Coomassie Blue
Absolute MeOH
Glacial Acetic Acid
H2 O

1.4 g
1L
140 mL
860 mL
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Destaining Solution
Absolute MeOH
Glacial Acetic Acid
H2 O

150 mL
200 mL
fill to 2 L

All SDS-PAGE gels were run using the BIO-RAD Mini Format 1-D
Electrophoresis Systems including the BIO-RAD PowerPacTM Basic and MiniPROTEAN® Tetra cell.
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APPENDIX G pJB2.274 Sequence
Sequence of multi-cloning site of pJB2.274 vector. Chloramphenicol resistance in
yellow, aroF gene in green, ubiC gene in light blue, sera in grey, tktA in brown.
Restriction enzymes EcoRI in Red, SacI in purple, and XbaI in teal. Sequence of primers
for mutagenesis of XhoI site is underlined, with the "A" not underlined to be changed to
"G."

TTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAGACCGTAAAGAAAAATA
AGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTTCGTATG
GCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAA
CTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAA
GATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTC
AGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCG
TTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCA
TGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAG
GGCGGGGCGTAATTTTTTTAAGGCAGTTATTGGTGCCTAGAAATATTTTATCTGATTAATAAGATGATCTT
CTTGAGATCGTTTTGGTCTGCGCGTAATCTCTTGCTCTGAAAACGAAAAAACCGCCTTGCAGGGCGGTTT
TTCGAAGGTTCTCTGAGCTACCAACTCTTTGAACCGAGGTAACTGGCTTGGAGGAGCGCAGTCACCAAAA
CTTGTCCTTTCAGTTTAGCCTTAACCGGCGCATGACTTCAAGACTAACTCCTCTAAATCAATTACCAGTGGC
TGCTGCCAGTGGTGCTTTTGCATGTCTTTCCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAG
CGGTCGGACTGAACGGGGGGTTCGTGCATACAGTCCAGCTTGGAGCGAACTGCCTACCCGGAACTGAGT
GTCAGGCGTGGAATGAGACAAACGCGGCCATAACAGCGGAATGACACCGGTAAACCGAAAGGCAGGAA
CAGGAGAGCGCACGAGGGAGCCGCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCC
ACCACTGATTTGAGCGTCAGATTTCGTGATGCTTGTCAGGGGGGCGGAGCCTATGGAAAAACGGCTTTG
CCGCGGCCCTCTCACTTCCCTGTTAAGTATCTTCCTGGCATCTTCCAGGAAATCTCCGCCCCGTTCGTAAGC
CATTTCCGCTCGCCGCAGTCGAACGACCGAGCGTAGCGAGTCAGTGAGCGAGGAAGCGGAATATATCCT
GTATCACATATTCTGCTGACGCACCGGTGCAGCCTTTTTTCTCCTGCCACATGAAGCACTTCACTGACACC
CTCATCAGTGCCAACATAGTAAGCCAGTATATACACTCCGCTAGCGCCCAATACGCAAACCGCCTCTCCCC
GCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGC
AACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTAT
GTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACATGATTACGAATTCTTAA
GCCACGCGAGCCGTCAGCTGCCCGTTCAGATCCTGATGAATTTCACGCAGCAAGGCATCGGTCATTTCCC
AGCTAATGCAGGCATCGGTTACGGATACACCGTATTTCATTTCACTGCGCGGTTGCTCGGAAGACTGATT
GCCCTCGTGGATATTACTTTCGATCATCAGACCAATAATTGAGCGATTGCCATCTTTGATTTGAGCAACCA
CGGATTCTGCCACCGCAGGCTGACGGCGATAATCTTTATTGGAATTACCGTGGCTGCAATCTACCATCAG
AGACGGGCGCAGTCCCGCCTGTTCCATCTCTTTTTCACATTGCGCAACATCCGCAGGGCTATAGTTCGGC
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GCTTTACCACCGCGCAGGATCACATGGCCGTCCGGATTCCCCTGAGTTTGTAGCAACGCAACCTGCCCTG
CCTGGTTAATGCCAACAAAACGGTGCGGCTGGGCGGCGGCGCGCATAGCGTTAATTGCTGTTGCCAGAC
TGCCGTCGGTGCCGTTTTTAAAACCAACCGGCATGGAAAGCCCGGAGGCCATTTCACGGTGAGTTTGCG
ATTCCGTTGTACGAGCACCAATTGCTGACCAGCTAAACAGATCGCCCAGGTATTGCGGGCTATTCAGATC
TAACGCTTCCGTCGCCAGTGGCAGTCCCATATTCACCAGCTCAAGCAGCAATTTACGCGCGATCTGCAGC
CCGGCTTCTACATCAAAAGAGCCATCCATATGGGGATCGTTAATTAACCCTTTCCAGCCGACAGTGGTAC
GGGGTTTTTCAAAATAGACGCGCATTACCAGATAGAGGCTATCGCTGACCTCTGCGGCAAGGGCTTTAAA
TCGACGAGCATATTCCAGAGCAGTTTCCGGATCATGAATGGAACAAGGACCACATACTACCAGCAGACG
AGGATCGCGCCCGGCGATAATATCTGAAATGCTTTTACGCGAGTCAGCAATCTGGGCTTCTTGTTGCAGG
CTCAATGGAAAAGCGGCCTTCAGTTGTTCCGGAGTCATTAAAACCTGTTCGTCGGTAATATGTACGTTATT
CAGCGCGTCTTTTTGCATGATGGCGATCCTGTTTATGCTCGTTTGCGATAGTTGATCCTCAGCGAGGATGA
CGTAACGATAACACATAAAGTAAAGTTTTCAATCCATATTTCGTACATTTTTATTTACACAGGCAATTTAGT
CGCGCTTTCAACCCTTACCTCTGTATAGATAAATTTACACTCCCTTTGAATTCGAGCTCGGTACCGAGCTGT
TGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGA
ATTCATGTCACACCCCGCGTTAACGCAACTGCGTGCGCTGCGCTATTGTAAAGAGATCCCTGCCCTGGAT
CCGCAACTGCTCGACTGGCTGTTGCTGGAGGATTCCATGACAAAACGTTTTGAACAGCAGGGAAAAACG
GTAAGCGTGACGATGATCCGCGAAGGGTTTGTCGAGCAGAATGAAATCCCCGAAGAACTGCCGCTGCTG
CCGAAAGAGTCTCGTTACTGGTTACGTGAAATTTTGTTATGTGCCGATGGTGAACCGTGGCTTGCCGGTC
GTACCGTCGTTCCTGTGTCAACGTTAAGCGGGCCGGAGCTGGCGTTACAAAAATTGGGTAAAACGCCGT
TAGGACGCTATCTGTTCACATCATCGACATTAACCCGGGACTTTATTGAGATAGGCCGTGATGCCGGGCT
GTGGGGGCGACGTTCCCGCCTGCGATTAAGCGGTAAACCGCTGTTGCTAACAGAACTGTTTTTACCGGC
GTCACCGTTGTACTAAGAGGGGTACCCGGGGATCCTCTAGAGTCAAACGAATGACGTTTACTTCGCTTTA
CCCTGGTTTGCAACCGCCGCTGCTTTCGCTGCGATCTCGTCAGCATTACCCAGATAATAGCGTTTCAGCGG
TTTGAAATTCTCGTCGAACTCATACACCAGCGGCACGCCAGTCGGGATATTAAGCTCAAGAATCCGACGC
AAACGTTCATATTGCCGCAATATTATTTTTTGATATGTTGAAAGGCGGATGCAAATCCGCACACAACATTT
CAAAAGACAGGATTGGGTAAATGGCAAAGGTATCGCTGGAGAAAGACAAGATTAAGTTTCTGCTGGTA
GAAGGCGTGCACCAAAAGGCGCTGGAAAGCCTTCGTGCAGCTGGTTACACCAACATCGAATTTCACAAA
GGCGCGCTGGATGATGAACAATTAAAAGAATCCATCCGCGATGCCCACTTCATCGGCCTGCGATCCCGTA
CCCATCTGACTGAAGACGTGATCAACGCCGCAGAAAAACTGGTCGCTATTGGCTGTTTCTGTATCGGAAC
AAACCAGGTTGATCTGGATGCGGCGGCAAAGCGCGGGATCCCGGTATTTAACGCACCGTTCTCAAATAC
GCGCTCTGTTGCGGAGCTGGTGATTGGCGAACTGCTGCTGCTATTGCGCGGCGTGCCGGAAGCCAATGC
TAAAGCGCACCGTGGCGTGTGGAACAAACTGGCGGCGGGTTCTTTTGAAGCGCGCGGCAAAAAGCTGG
GTATCATCGGCTACGGTCATATTGGTACGCAATTGGGCATTCTGGCTGAATCGCTGGGAATGTATGTTTA
CTTTTATGATATTGAAAATAAACTGCCGCTGGGCAACGCCACTCAGGTACAGCATCTTTCTGACCTGCTGA
ATATGAGCGATGTGGTGAGTCTGCATGTACCAGAGAATCCGTCCACCAAAAATATGATGGGCGCGAAAG
AAATTTCACTAATGAAGCCCGGCTCGCTGCTGATTAATGCTTCGCGCGGTACTGTGGTGGATATTCCGGC
GCTGTGTGATGCGCTGGCGAGCAAACATCTGGCGGGGGCGGCAATCGACGTATTCCCGACGGAACCGG
CGACCAATAGCGATCCATTTACCTCTCCGCTGTGTGAATTCGACAACGTCCTTCTGACGCCACACATTGGC
GGTTCGACTCAGGAAGCGCAGGAGAATATCGGCCTGGAAGTTGCGGGTAAATTGATCAAGTATTCTGAC
AATGGCTCAACGCTCTCTGCGGTGAACTTCCCGGAAGTCTCGCTGCCACTGCACGGTGGGCGTCGTCTGA
TGCACATCCACGAAAACCGTCCGGGCGTGCTAACTGCGCTGAACAAAATCTTCGCCGAGCAGGGCGTCA
ACATCGCCGCGCAATATCTGCAAACTTCCGCCCAGATGGGTTATGTGGTTATTGATATTGAAGCCGACGA
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AGACGTTGCCGAAAAAGCGCTGCAGGCAATGAAAGCTATTCCGGGTACCATTCGCGCCCGTCTGCTGTA
CTAATTCCCCTTCTCTGAAAATCAACGGGCAGGTCACTGACTTGCCCGTTTTTTTATCCCTTCTCCACACCG
TTGCCGCGTTGCGCATTCTACTTTGCGAGTCTGCTCCAGAAAANNNTAAATCAAAGTCAGATCAATGCGT
TGTGTTTATTTAATGGGGATTTACGATGGCAGGGCAGCATGGGGCTGTAACGGTAAAGCCCTCACCGAA
GCGAGGGCTTGAAGGAGAAGGGTTATGATGCGACTTGTCATCATACTGATTGTACTGTTACTCATAAGTT
TCAGCGCTTATTAACAGTCAGTCTCAGGGGAGGAGCAATCCTCCCTTACCCTTACTCACTAAATTAGGTCA
AAGAATCAACGATGTCAATCAGGGCGATGCGGGTGTATCGCCCTTACCACTCCCAGACTTTCGACGGTGT
AACCACCGCAGGAAGAGGGATGACCTGCAGGCATGCAAGCTTCCAGAGATTTCTGAAGCGGCAAAAGG
ATGTTCCATGTACATGACGCGCGGCTTGCGGTAAATTGTTGGCAAATTTTCCGGCGTAGCCCAAAACGCG
CTGTCGTCAAGTCGTTAAGGGCGTGCCCTTCATCATCCGATCTGGAGTCAAAATGTCCTCACGTAAAGAG
CTTGCCAATGCTATTCGTGCGCTGAGCATGGACGCAGTACAGAAAGCCAAATCCGGTCACCCGGGTGCC
CCTATGGGTATGGCTGACATTGCCGAAGTCCTGTGGCGTGATTTCCTGAAACACAACCCGCAGAATCCGT
CCTGGGCTGACCGTGACCGCTTCGTGCTGTCCAACGGCCACGGCTCCATGCTGATCTACAGCCTGCTGCA
CCTCACCGGTTACGATCTGCCGATGGAAGAACTGAAAAACTTCCGTCAGCTGCACTCTAAAACTCCGGGT
CACCCGGAAGTGGGTTACACCGCTGGTGTGGAAACCACCACCGGTCCGCTGGGTCAGGGTATTGCCAAC
GCAGTCGGTATGGCGATTGCAGAAAAAACGCTGGCGGCGCAGTTTAACCGTCCGGGCCACGACATTGTC
GACCACTACACCTACGCCTTCATGGGCGACGGCTGCATGATGGAAGGCATCTCCCACGAAGTTTGCTCTC
TGGCGGGTACGCTGAAGCTGGGTAAACTGATTGCATTCTACGATGACAACGGTATTTCTATCGATGGTCA
CGTTGAAGGCTGGTTCACCGACGACACCGCAATGCGTTTCGAAGCTTACGGCTGGCACGTTATTCGCGAC
ATCGACGGTCATGACGCGGCATCTATCAAACGCGCAGTAGAAGAAGCGCGCGCAGTGACTGACAAACCT
TCCCTGCTGATGTGCAAAACCATCATCGGTTTCGGTTCCCCGAACAAAGCCGGTACCCACGACTCCCACG
GTGCGCCGCTGGGCGACGCTGAAATTGCCCTGACCCGCGAACAACTGGGCTGGAAATATGCGCCGTTCG
AAATCCCGTCTGAAATCTATGCTCAGTGGGATGCGAAAGAAGCAGGCCAGGCGAAAGAATCCGCATGG
AACGAGAAATTCGCTGCTTACGCGAAAGCTTATCCGCAGGAAGCCGCTGAATTTACCCGCCGTATGAAA
GGCGAAATGCCGTCTGACTTCGACGCTAAAGCGAAAGAGTTCATCGCTAAACTGCAGGCTAATCCGGCG
AAAATCGCCAGCCGTAAAGCGTCTCAGAATGCTATCGAAGCGTTCGGTCCGCTGTTGCCGGAATTCCTCG
GCGGTTCTGCTGACCTGGCGCCGTCTAACCTGACCCTGTGGTCTGGTTCTAAAGCAATCAACGAAGATGC
TGCGGGTAACTACATCCACTACGGTGTTCGCGAGTTCGGTATGACCGCGATTGCTAACGGTATCTCCCTG
CACGGTGGCTTCCTGCCGTACACCTCCACCTTCCTGATGTTCGTGGAATACGCACGTAACGCCGTACGTAT
GGCTGCGCTGATGAAACAGCGTCAGGTGATGGTTTACACCCACGACTCCATCGGTCTGGGCGAAGACGG
CCCGACTCACCAGCCGGTTGAGCAGGTCGCTTCTCTGCGCGTAACCCCGAACATGTCTACATGGCGTCCG
TGTGACCAGGTTGAATCCGCGGTCGCGTGGAAATACGGTGTTGAGCGTCAGGACGGCCCGACCGCACTG
ATCCTCTCCCGTCAGAACCTGGCGCAGCAGGAACGAACTGAAGAGCAACTGGCAAACATCGCGCGCGGT
GGTTATGTGCTGAAAGACTGCGCCGGTCAGCCGGAACTGATTTTCATCGCTACCGGTTCAGAAGTTGAAC
TGGCTGTTGCTGCCTACGAAAAACTGACTGCCGAAGGCGTGAAAGCGCGCGTGGTGTCCATGCCGTCTA
CCGACGCATTTGACAAGCAGGATGCTGCTTACCGTGAATCCGTACTGCCGAAAGCGGTTACTGCACGCGT
TGCTGTAGAAGCGGGTATTGCTGACTACTGGTACAAGTATGTTGGCCTGAACGGTGCTATCGTCGGTATG
ACCACCTTCGGTGAATCTGCTCCGGCAGAGCTGCTGTTTGAAGAGTTCGGCTTCACTGTTGATAACGTTG
TTGCGAAAGCAAAAGAACTGCTGTAATTAGCATTTCGGGTAAAAAGGTCGCTTCGGCGACCTTTTTTATT
ACCTTGATATGTCCGTTTGCGGACCAGGATCAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGG
GAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCG
AAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTGATGTCCGG
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CGGTGCTTTTGCCGTTACGCACCACCCCGTCAGTAGCTGAACAGGAGGGACAGCTGATAGAAACAGAAG
CCACTGGAGCACCTCAAAAACACCATCATACACTAAATCAGTAAGTTGGCAGCATCACCCGACGCACTTT
GCGCCGAATAAATACCTGTGACGGAAGATCACTTCGCAGAATAAATAAATCCTGGTGTCCCTGTTGATAC
CGGGAAGCCCTGGGCCAACTTTTGGCGAAAATGAGACGTTGATCGGCACGTAAGAGGTTCCAACTTTCA
CCATAATGAAATAAGATCACTACCGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCT
AAAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTG
ACTGAAATGCCTCAG
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APPENDIX H aroC and tyrB sequences
aroC gene with EcoRI in red and XbaI in teal.
GAATTCATGTTGTCTTTAAGGTATTTGACATTTCTGACAGCCGGAGAGTCCCACGGTAAGGGTTTGACCG
CAATACTGGAGGGTATACCCGCAAACTTACCCCTTTCCGAAGAGGAAATAAACCACGAACTCAGGAGAA
GGCAAAGGGGATACGGGCGCGGCGGTCGTATGAAGATAGAAAAGGACACCGCGGAAATACTCTCGGG
TGTCAGGTTCGGAAAAACCCTCGGCTCTCCCATAGCCCTCTTTATAAGGAACAGGGACTGGGAAAACTGG
AAGGAAAAGATGGCGATAGAGGGGGAACCCTCCCCTTCCGTTGTTCCCTTCACGAGACCCCGCCCGGGG
CACGCTGACCTCTCCGGAGGGATTAAGTACAACCAGAGGGATTTGAGGAACATTTTAGAGAGGGCTTCT
GCAAGAGAGACAGCTGCAAGAGTTGCGGTAGGAGCTGTTTGTAAAAAGTTCCTCTCTGAATTTGGTATA
AAGATCGGGAGTTTCGTTGTAAGCATAGGCCAAAAGGAAGTGGAGGAGTTAAAAGACAAAAGCTACTTT
GCCAATCCTGAAAAACTCCTTTCTTACCACGAGAAAGCGGAAGATTCGGAACTCAGGATTCCCTTCCCGG
AGAAGGACGAGGAGTTTAAAACCTACATAGACGAGGTGAAGGAAAAGGGAGAGAGTTTAGGAGGAGT
TTTCGAAGTTTTTGCCCTGAACGTCCCTCCGGGACTCGGTTCTCACATCCAGTGGGACAGAAGGATTGAC
GGAAGGATAGCTCAGGCGATGATGAGCATTCAGGCCATTAAAGGCGTTGAGATAGGACTTGGTTTTGAA
GCCGCGAGGAGGTTCGGCTCTCAGGTTCACGACGAGATAGGCTGGAGTGAAGGGAAGGGCTACTTCAG
GCATTCTAACAACCTCGGAGGAACGGAAGGAGGGATCACAAACGGCATGCCGATAGTTGTGAGAGTCG
CGATGAAACCCATACCGACTTTAAAGAACCCTTTAAGGAGTGTTGATATAGAAACAAAGGAAGAGATGA
AAGCAGGAAAGGAGAGGACGGATATAGTAGCAGTTCCCGCGGCATCTGTCGTGGGAGAAGCTATGCTC
GCCATAGTTCTCGCGGATGCACTCCTTGAAAAACTCGGCGGAGACTTTATGGAAGAACGTAAAAACGAG
GTTTGATAATCTAGA

tyrB gene with EcoRI in red and XbaI in teal
GAATTCGTGTTTCAAAAAGTTGACGCCTACGCTGGCGACCCGATTCTTACGCTTATGGAGCGTTTTAAAG
AAGACCCTCGCAGCGACAAAGTGAATTTAAGTATCGGTCTGTACTACAACGAAGACGGAATTATTCCACA
ACTGCAAGCCGTGGCGGAGGCGGAAGCGCGCCTGAATGCGCAGCCTCATGGCGCTTCGCTTTATTTACC
GATGGAAGGGCTTAACAGCTATCGCCATGCCATTGCGCCGCTGCTGTTTGGTGCGGACCATCCAGTACTG
CAACAACAGCGCGTAGCAACCATTCAAACCCTTGGCGGCTCAGGGGCATTGAAAGTGGGCGCGGATTTC
CTGAAACGCTACTTCCCGGAATCAGGCGTCTGGGTCAGCGATCCTACCTGGGAAAACCACGTAGCAATAT
TCGCCGGGGCTGGATTCGAAGTGAGTACTTACCCCTGGTATGACGAAGCGACTAACGGCGTGCGCTTTA
ATGACCTGTTGGCGACGCTGAAAACATTACCTGCCCGCAGTATTGTGTTGCTGCATCCATGTTGCCACAA
CCCAACGGGTGCCGATCTCACTAATGATCAGTGGGATGCGGTGATTGAAATTCTCAAATCCCGCGAGCTT
ATTCCATTCCTCGATATTGCCTATCAAGGATTTGGTGCCGGTATGGAAGAGGATGCCTACGCTATTCGCG
CCATTGCCAGCGCTGGATTACCCGCTCTGGTGAGCAATTCGTTCTCGAAAATTTTCTCCCTTTACGGCGAG
CGCGTCGGCGGACTTTCTGTTCTGTGTGAAGATGCCGAAGCCGCTGGCCGCGTACTGGGGCAATTGAAA
GCAACAGTTCGCCGCAACTACTCCAGCCCGCCGAATTTTGGTGCGCAGGTGGTGGCTGCAGTGCTGAAT
GACGAGGCATTGAAAGCCAGCTGGCTGGCGGAAGTAGAAGAGATGCGTACTCGCATTCTGGCAATGCG
TCAGGAACTGGTGAAGGTATTAAGCACAGAGATGCCAGAACGCAATTTCGATTATCTGCTTAATCAGCGC
GGCATGTTCAGTTATACCGGTTTAAGTGCCGCTCAGGTTGACCGACTACGTGAAGAATTTGGTGTCTATC
TCATCGCCAGCGGTCGCATGTGTGTCGCCGGGTTAAATACGGCAAATGTACAACGTGTGGCAAAGGCGT
TTGCTGCGGTGATGTAATGATCTAGA
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APPENDIX I ydiB and aroK Sequences
ydiB gene with XbaI in teal and XhoI in pink
TCTAGAAAGGAGGAACAGACATGGATGTTACCGCAAAATACGAATTGATTGGGCTGATGGCCTATCCTA
TCCGCCACAGTTTATCGCCTGAAATGCAGAATAAAGCCTTAGAAAAAGCGGGATTGCCATTTACCTATAT
GGCCTTTGAAGTGGATAACGATAGTTTTCCCGGAGCAATTGAAGGATTAAAAGCCCTCAAAATGCGCGG
AACTGGTATATCAATGCCGAACAAACAACTGGCGTGTGAATATGTTGATGAATTAACGCCAGCAGCCAA
ACTGGTGGGTGCCATCAACACCATCGTTAATGATGATGGCTACCTGCGCGGCTATAACACCGACGGCAC
GGGCCATATTCGCGCCATTAAAGAGAGCGGTTTTGATATCAAAGGCAAAACAATGGTGCTGTTAGGGGC
CGGAGGTGCCTCAACGGCGATTGGCGCGCAGGGGGCAATTGAAGGTTTAAAAGAAATTAAACTCTTTAA
CCGTCGGGATGAGTTCTTCGATAAAGCCCTCGCCTTCGCGCAGCGGGTTAACGAAAACACCGATTGTGTC
GTCACGGTTACCGATCTCGCCGATCAGCAAGCCTTTGCTGAAGCCCTGGCTTCCGCCGACATTTTAACCAA
TGGCACAAAAGTGGGTATGAAACCCCTTGAGAATGAATCATTAGTTAATGATATCAGTCTGTTACATCCG
GGACTGCTGGTCACTGAATGCGTGTATAACCCGCATATGACGAAGTTATTGCAGCAGGCGCAACAAGCG
GGTTGCAAAACGATTGATGGATACGGCATGTTGTTGTGGCAAGGGGCTGAACAGTTCACGTTATGGACT
GGCAAAGATTTCCCTCTGGAATATGTTAAACAGGTCATGGGGTTCGGTGCCTGACTCGAG

aroK gene with XbaI in teal and XhoI in pink
TCTAGAGGAGGAACAGACATGGCAGAGAAACGCAATATCTTTCTGGTTGGGCCTATGGGTGCCGGAAAA
AGCACTATTGGGCGCCAGTTAGCTCAACAACTCAATATGGAATTTTACGATTCCGATCAAGAGATTGAGA
AACGAACCGGAGCTGATGTGGGCTGGGTTTTCGATTTAGAAGGCGAAGAAGGCTTCCGCGATCGCGAA
GAAAAGGTCATCAATGAGTTGACCGAGAAACAGGGTATTGTGCTGGCTACTGGCGGCGGCTCTGTGAAA
TCCCGTGAAACGCGTAACCGTCTTTCCGCTCGTGGCGTTGTCGTTTATCTTGAAACGACCATCGAAAAGC
AACTTGCACGCACGCAGCGTGATAAAAAACGCCCGTTGCTGCACGTTGAAACACCGCCGCGTGAAGTTCT
GGAAGCGTTGGCCAATGAACGCAATCCGCTGTATGAAGAGATTGCCGACGTGACCATTCGTACTGATGA
TCAAAGCGCTAAAGTGGTTGCAAACCAGATTATTCACATGCTGGAAAGCAACTAACTCGAG

130

REFERENCES
1.

Bogan, A.A. and K.S. Thorn, Anatomy of hot spots in protein interfaces. J Mol Biol, 1998.
280(1): p. 1-9.

2.

Goto, N.K. and L.E. Kay, New developments in isotope labeling strategies for protein
solution NMR spectroscopy. Current Opinion in Structural Biology, 2000. 10(5): p. 585592.

3.

Verardi, R., et al., Isotope Labeling for Solution and Solid-State NMR Spectroscopy of
Membrane Proteins, in Isotope labeling in Biomolecular NMR, H.S. Atreya, Editor 2012,
Springer Netherlands. p. 35-62.

4.

Ikura, M., L.E. Kay, and A. Bax, A novel approach for sequential assignment of 1H, 13C,
and 15N spectra of proteins: heteronuclear triple-resonance three-dimensional NMR
spectroscopy. Application to calmodulin. Biochemistry. 1990 May 15;29(19):4659-67.,
1990.

5.

Sanders, C.R. and F. Sonnichsen, Solution NMR of membrane proteins: practice and
challenges. Magn Reson Chem, 2006. 44 Spec No: p. S24-40.

6.

Becker, E.D., A brief history of nuclear magnetic resonance. Anal Chem, 1993. 65(6): p.
295A-302A.

7.

Arnold, J.T., S.S. Dharmatti, and M.E. Packard, Chemical Effects on Nuclear Induction
Signals from Organic Compounds. The Journal of Chemical Physics, 1951. 19(4): p. 507.

8.

Ramsey, N.F. and E.M. Purcell, Interactions between Nuclear Spins in Molecules. Physical
Review, 1952. 85(1): p. 143-144.

9.

Bloch, F., Nuclear Induction. Physical Review, 1946. 70(7-8): p. 460-474.

10.

Hahn, E.L., An Accurate Nuclear Magnetic Resonance Method for Measuring Spin-Lattice
Relaxation Times. Physical Review, 1949. 76(1): p. 145-146.

11.

Shoolery, J.N. and M.T. Rogers, Nuclear Magnetic Resonance Spectra of Steroids. Journal
of the American Chemical Society, 1958. 80(19): p. 5121-5135.

12.

Kallmann, H. and M. Pope, Photovoltaic Effect in Organic Crystals. The Journal of
Chemical Physics, 1959. 30(2): p. 585-586.

13.

Zechmeister, L. and L.M. Jackman, Some Applications of Nuclear Magnetic Resonance
Spectroscopy in Natural Product Chemistry, in Fortschritte der Chemie Organischer
Naturstoffe / Progress in the Chemistry of Organic Natural Products / ProgrÃ¨s dans la
Chimie des Substances Organiques Naturelles1965, Springer Vienna. p. 315-362.

131

14.

Anet, F.A.L. and A.J.R. Bourn, Nuclear Magnetic Resonance Spectral Assignments from
Nuclear Overhauser Effects1. Journal of the American Chemical Society, 1965. 87(22): p.
5250-5251.

15.

Paul, C.L., C[sup 13] Nuclear Magnetic Resonance Spectra. The Journal of Chemical
Physics, 1957. 26(1): p. 217-218.

16.

Saunders, M., A. Wishnia, and J.G. Kirkwood, THE NUCLEAR MAGNETIC RESONANCE
SPECTRUM OF RIBONUCLEASE1. Journal of the American Chemical Society, 1957. 79(12):
p. 3289-3290.

17.

McDonald, C.C., Phillips, W.D., In: Magnetic Resonance in Biological Systems, ed. A.
Ehrenberg, Malmström, B. G., Vänngård, T1967, Oxford: Pergamon Press.

18.

Lowe, I.J. and R.E. Norberg, Free-Induction Decays in Solids. Physical Review, 1957.
107(1): p. 46-61.

19.

Ernst, R.R. and W.A. Anderson, Application of Fourier Transform Spectroscopy to
Magnetic Resonance. Review of Scientific Instruments, 1966. 37(1): p. 93-102.

20.

Aue, W.P., E. Bartholdi, and R.R. Ernst, Two-dimensional spectroscopy. Application to
nuclear magnetic resonance. The Journal of Chemical Physics, 1976. 64(5): p. 2229-2246.

21.

Bax, A. and L. Lerner, Two-dimensional nuclear magnetic resonance spectroscopy.
Science. 1986 May 23;232(4753):960-7., 1986.

22.

Nagayama, K., et al., Selective spin decoupling in the J-resolved two-dimensional 1H
n.m.r. spectra of proteins. Biochemical and Biophysical Research Communications, 1979.
86(1): p. 218-225.

23.

Clore, G.M. and A.M. Gronenborn, Determination of three-dimensional structures of
proteins and nucleic acids in solution by nuclear magnetic resonance spectroscopy.
Critical reviews in biochemistry and molecular biology, 1989. 24(5): p. 479-564.

24.

Williamson, M.P., T.F. Havel, and K. Wuthrich, Solution conformation of proteinase
inhibitor IIA from bull seminal plasma by 1H nuclear magnetic resonance and distance
geometry. J Mol Biol. 1985 Mar 20;182(2):295-315., 1985.

25.

Ohki, S.-y. and M. Kainosho, Stable isotope labeling methods for protein NMR
spectroscopy. Progress in Nuclear Magnetic Resonance Spectroscopy, 2008. 53(4): p.
208-226.

26.

Gardner, K., Rosen, M., Kay, L., Global Folds of Highly Deuterared, Methyl-Protonated
Proteins by Multidimensional NMR. Biochemistry, 1997. 36: p. 1389-1401.

27.

Goto, N., Kay, L., New Developments in isotope labeling strategies for protein solution
NMR spectroscopy. Current Opinion in Structural Biology, 2000. 10: p. 585-592.

132

28.

Kato, H., et al., Architecture of the high mobility group nucleosomal protein 2nucleosome complex as revealed by methyl-based NMR. Proceedings of the National
Academy of Sciences, 2011. 108(30): p. 12283-12288.

29.

Kim, H.J., et al., Recent advances in the application of solution NMR spectroscopy to
multi-span integral membrane proteins. Progress in Nuclear Magnetic Resonance
Spectroscopy, 2009. 55(4): p. 335-360.

30.

Tugarinov, V. and L.E. Kay, Ile, Leu, and Val Methyl Assignments of the 723-Residue
Malate Synthase G Using a New Labeling Strategy and Novel NMR Methods. Journal of
the American Chemical Society, 2003. 125(45): p. 13868-13878.

31.

Zhang, G., Neubert, T.A., , Use of stable isotope labeling by amino acids in cell culture
(SILAC) for phophotyrosine protein identification and quantitation Methods in Molecular
Biology, 2009. 527: p. 79-92.

32.

Sprangers, R. and L.E. Kay, Quantitative dynamics and binding studies of the 20S
proteasome by NMR. Nature, 2007. 445(7128): p. 618-22.

33.

Kim, H.W., et al., The specific incorporation of labelled aromatic amino acids into
proteins through growth of bacteria in the presence of glyphosate. Application to
fluorotryptophan labelling to the H(+)-ATPase of Escherichia coli and NMR studies. FEBS
Lett, 1990. 272(1-2): p. 34-6.

34.

McCaldon, P. and P. Argos, Oligopeptide biases in protein sequences and their use in
predicting protein coding regions in nucleotide sequences. Proteins, 1988. 4(2): p. 99122.

35.

Isaacson, R.L., et al., A new labeling method for methyl transverse relaxation-optimized
spectroscopy NMR spectra of alanine residues. J Am Chem Soc, 2007. 129(50): p. 154289.

36.

Tjong, H., S. Qin, and H.X. Zhou, PI2PE: protein interface/interior prediction engine.
Nucleic Acids Res, 2007. 35(Web Server issue): p. W357-62.

37.

FernÃ¡ndez, A., L.R. Scott, and H.A. Scheraga, Amino Acid Residues at Proteinâˆ’Protein
Interfaces:â€‰ Why Is Propensity so Different from Relative Abundance? The Journal of
Physical Chemistry B, 2003. 107(36): p. 9929-9932.

38.

Ayala, I., et al., An efficient protocol for the complete incorporation of methyl-protonated
alanine in perdeuterated protein. J Biomol NMR, 2009. 43(2): p. 111-9.

39.

Velyvis, A., A.M. Ruschak, and L.E. Kay, An economical method for production of (2)H,
(13)CH3-threonine for solution NMR studies of large protein complexes: application to
the 670 kDa proteasome. Plos One, 2012. 7(9): p. e43725-e43725.

40.

Sinha, K., L. Jen-Jacobson, and G.S. Rule, Specific Labeling of Threonine Methyl Groups
for NMR Studies of Protein‚ÄìNucleic Acid Complexes. Biochemistry, 2011. 50(47): p.
10189-10191.
133

41.

Bogan, A., Thorn, K., Anatomy of Hot Spots in Protein Interfaces. J. Mol. Biol. 1998. 280:
p. 1-9.

42.

Ben-Shimon, A. and M. Eisenstein, Computational Mapping of Anchoring Spots on
Protein Surfaces. Journal of Molecular Biology, 2010. 402(1): p. 259-277.

43.

Mcfeeters, R., Xiong, C., O’Keefe, B., Bokesh, K., McMahon, J., Ratner, D., Castelli, R.,
Seeberger, P., Byrd, R. , Letter to the Editor: Semi-automated backbone resonance
assignments of the extracellular ligand-binding domain of an ionotropic glutamate
receptor. J. Biomol. NMR, 2007. 22: p. 297-298.

44.

Truhlar, S., Cervantes, C., Torpey, J., Kjaergaard, M., Komives, E., Rapid mass
spectrometric analysis of 15N-Leu incorporation fidelity during preparation of specifically
labeled NMR samples. Protein Science, 2008. 17: p. 1636-1639.

45.

Gelfand, D.H. and R.A. Steinberg, Escherichia coli mutants deficient in the aspartate and
aromatic amino acid aminotransferases. J Bacteriol, 1977. 130(1): p. 429-40.

46.

Churchill, C.D.M., L.R. Rutledge, and S.D. Wetmore, Effects of the biological backbone on
stacking interactions at DNA-protein interfaces: the interplay between the
backbone[small pi] and [small pi][small pi] components. Physical Chemistry Chemical
Physics, 2010. 12(43).

47.

Schneider, H.-J., Binding Mechanisms in Supramolecular Complexes. Angewandte
Chemie International Edition, 2009. 48(22): p. 3924-3977.

48.

Ikeda, M., Towards bacterial strains overproducing L-tryptophan and other aromatics by
metabolic engineering. Appl Microbiol Biotechnol, 2006. 69(6): p. 615-26.

49.

Zhou, H., et al., Enhanced L-phenylalanine production by recombinant Escherichia coli
BR-42 (pAP-B03) resistant to bacteriophage BP-1 via a two-stage feeding approach. J Ind
Microbiol Biotechnol, 2010. 38(9): p. 1219-27.

50.

Leuchtenberger, W., K. Huthmacher, and K. Drauz, Biotechnological production of amino
acids and derivatives: current status and prospects. Appl Microbiol Biotechnol, 2005.
69(1): p. 1-8.

51.

Sprenger, G.A., From scratch to value: engineering Escherichia coli wild type cells to the
production of L-phenylalanine and other fine chemicals derived from chorismate. Appl
Microbiol Biotechnol, 2007. 75(4): p. 739-49.

52.

Hermann, T., Industrial production of amino acids by coryneform bacteria. J Biotechnol,
2003. 104(1-3): p. 155-72.

53.

Snell, K.D., K.M. Draths, and J.W. Frost, Synthetic Modification of the Escherichia coli
Chromosome: Enhancing the Biocatalytic Conversion of Glucose into Aromatic
Chemicals. Journal of the American Chemical Society, 1996. 118(24): p. 5605-5614.

134

54.

Kanehisa, M., et al., KEGG for integration and interpretation of large-scale molecular
data sets. Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14. doi:
10.1093/nar/gkr988. Epub 2011 Nov 10., 2011.

55.

Lutke-Eversloh, T. and G. Stephanopoulos, Combinatorial pathway analysis for improved
L-tyrosine production in Escherichia coli: identification of enzymatic bottlenecks by
systematic gene overexpression. Metab Eng, 2008. 10(2): p. 69-77.

56.

LeMaster, D.M. and F.M. Richards, Preparative-scale isolation of isotopically labeled
amino acids. Analytical Biochemistry, 1982. 122(2): p. 238-247.

57.

LeMaster, D.M. and J.E. Cronan, Biosynthetic production of 13C-labeled amino acids with
site-specific enrichment. Journal of Biological Chemistry, 1982. 257(3): p. 1224-1230.

58.

Yi, J., et al., Altered glucose transport and shikimate pathway product yields in E. coli.
Biotechnol Prog, 2003. 19(5): p. 1450-9.

59.

Santos, C.N., W. Xiao, and G. Stephanopoulos, Rational, combinatorial, and genomic
approaches for engineering L-tyrosine production in Escherichia coli. Proc Natl Acad Sci U
S A, 2012. 109(34): p. 13538-43.

60.

Weber, P.L., S.C. Brown, and L. Mueller, Sequential proton NMR assignments and
secondary structure identification of human ubiquitin. Biochemistry, 1987. 26(23): p.
7282-7290.

61.

Wilson, R., Hughes, R., Flatt, J., Meehan, E., Ng, J., Twigg, P., Structure of full-length
ubiquitin-conjugating enzyme E2-25K (huntington-interacting protein 2). Structural
Biology and Crystallization Communications, 2009. 65(Part 5): p. 440-444.

62.

Pickart, C.M., Ubiquitin Enters the New Millennium. Molecular Cell, 2001. 8(3): p. 499504.

63.

Das, G. and U. Varshney, Peptidyl-tRNA hydrolase and its critical role in protein
biosynthesis. Microbiology (Reading, England), 2006. 152: p. 2191-5.

64.

Schmitt, E., et al., Crystal structure at 1.2 A resolution and active site mapping of
Escherichia coli peptidyl-tRNA hydrolase. The EMBO journal, 1997. 16(15): p. 4760-4769.

65.

Hughes, R.C., et al., Recombinant production, crystallization and X-ray crystallographic
structure determination of the peptidyl-tRNA hydrolase of Pseudomonas aeruginosa.
Acta Crystallogr Sect F Struct Biol Cryst Commun, 2012. 68(Pt 12): p. 1472-6.

66.

Goodall, J.J., G.J. Chen, and M.G. Page, Essential role of histidine 20 in the catalytic
mechanism of Escherichia coli peptidyl-tRNA hydrolase. Biochemistry, 2004. 43(15): p.
4583-91.

67.

Cruz-Vera, L.R., et al., The rate of peptidyl-tRNA dissociation from the ribosome during
minigene expression depends on the nature of the last decoding interaction. The Journal
of biological chemistry, 2003. 278: p. 26065-70.
135

68.

Harris, S.M., et al., Peptidyl-tRNA hydrolase screening combined with molecular docking
reveals the antibiotic potential of Syzygium johnsonii bark extract. Nat Prod Commun.
2011 Oct;6(10):1421-4., 2011.

69.

Caplan, A.B. and J.R. Menninger, Dissociation of peptidyl-tRNA from ribosomes is
perturbed by streptomycin and by strA mutations. Molecular & general genetics : MGG,
1984. 194: p. 534-8.

70.

Cruz-Vera, L.R., J.M. Galindo, and G. Guarneros, Transcriptional analysis of the gene
encoding peptidyl-tRNA hydrolase in Escherichia coli. Microbiology (Reading, England),
2002. 148: p. 3457-66.

71.

Cruz-Vera, L.R., et al., Ribosome stalling and peptidyl-tRNA drop-off during translational
delay at AGA codons. Nucleic acids research, 2004. 32: p. 4462-8.

72.

Ito, K., et al., Structural basis for the substrate recognition and catalysis of peptidyl-tRNA
hydrolase. Nucleic Acids Research, 2012. 40(20): p. 10521-10531.

73.

Siebert, M., K. Severin, and L. Heide, Formation of 4-hydroxybenzoate in Escherichia coli:
characterization of the ubiC gene and its encoded enzyme chorismate pyruvate-lyase.
Microbiology, 1994. 140 (Pt 4): p. 897-904.

74.

Barker, J.L. and J.W. Frost, Microbial synthesis of p-hydroxybenzoic acid from glucose.
Biotechnol Bioeng, 2001. 76(4): p. 376-90.

75.

Charles, I.G., et al., Isolation, characterization and nucleotide sequences of the aroC
genes encoding chorismate synthase from Salmonella typhi and Escherichia coli. J Gen
Microbiol. 1990 Feb;136(2):353-8., 1990.

76.

Nakai, Y., H. Hayashi, and H. Kagamiyama, Cloning and characterization of the tyrB gene
from Salmonella typhimurium. Biochim Biophys Acta. 1996 Sep 11;1308(3):189-92.,
1996.

77.

Band, L., H. Shimotsu, and D.J. Henner, Nucleotide sequence of the Bacillus subtilis trpE
and trpD genes. Gene, 1984. 27(1): p. 55-65.

78.

Menzella, H.G., E.A. Ceccarelli, and H.C. Gramajo, Novel escherichia coli strain allows
efficient recombinant protein production using lactose as inducer. Biotechnol Bioeng,
2003. 82(7): p. 809-17.

79.

Edmondson, S., Shriver, J., DNA-Binding Proteins Sac7d and Sso7d from Sulfolobus.
Methods in Enzymology 2001. 334: p. 129-45.

80.

Delaglio, F., et al., NMRPipe: a multidimensional spectral processing system based on
UNIX pipes. J Biomol NMR, 1995. 6(3): p. 277-93.

81.

Goddard , T.D. and D.G. Kneller, SPARKY 3. University of California, San Francisco.

136

82.

Svergun, D., Determination of the regularization parameter in indirect-transform
methods using perceptual criteria. Journal of Applied Crystallography, 1992. 25(4): p.
495-503.

83.

Guinier, A., La diffraction des rayons X aux tres petits angles: applications a l'etude de
phenomenes ultramicroscopiques. Annales de physique, 1939. 11. 12.1939: p. 161-237.

84.

Svergun, D.I., Restoring low resolution structure of biological macromolecules from
solution scattering using simulated annealing. Biophys J, 1999. 76(6): p. 2879-86.

85.

Pettersen, E.F., et al., UCSF Chimera--a visualization system for exploratory research and
analysis. J Comput Chem, 2004. 25(13): p. 1605-12.

86.

Kim, H., Perez, J., Ferguson, S., Campbell, I., The specific incorporation of labelled
aromatic amino acids into proteins thrhough growth of bacteria in the presence of
glyphosate. FEBS, 1990. 272(1,2): p. 34-36.

87.

Kline, S., Reduction and analysis of SANS and USANS data using IGOR Pro. Journal of
Applied Crystallography, 2006. 39(6): p. 895-900.

88.

Selvaraj, M., et al., Structural plasticity and enzyme action: crystal structures of
mycobacterium tuberculosis peptidyl-tRNA hydrolase. J Mol Biol, 2007. 372(1): p. 18693.

89.

Ito, K., et al., Structural basis for the substrate recognition and catalysis of peptidyl-tRNA
hydrolase. Nucleic Acids Res, 2012. 40(20): p. 10521-31.

90.

Kozin, M.B. and D.I. Svergun, Automated matching of high- and low-resolution structural
models. J Appl Cryst, 2001. 34: p. 33-41.

91.

Giege, R., Toward a more complete view of tRNA biology. Nature structural & molecular
biology, 2008. 15(10): p. 1007-14.

92.

Alexander, R.W., J. Eargle, and Z. Luthey-Schulten, Experimental and computational
determination of tRNA dynamics. FEBS letters, 2010. 584(2): p. 376-86.

93.

Wang, J., et al., Comparative study of L-phenylalanine production in the growing and
stationary phases during high cell density cultivation of an auxotrophic Escherichia coli.
Biotechnology and Bioprocess Engineering, 2011. 16(5): p. 916-922.

94.

Ikeda, M. and R. Katsumata, Metabolic Engineering To Produce Tyrosine or
Phenylalanine in a Tryptophan-Producing Corynebacterium glutamicum Strain. Appl
Environ Microbiol, 1992. 58(3): p. 781-5.

95.

Baez-Viveros, J.L., et al., Metabolic engineering and protein directed evolution increase
the yield of L-phenylalanine synthesized from glucose in Escherichia coli. Biotechnol
Bioeng, 2004. 87(4): p. 516-24.

137

96.

Krishnarjuna, B., et al., Amino acid selective unlabeling for sequence specific resonance
assignments in proteins. J Biomol NMR, 2010. 49(1): p. 39-51.

97.

McFeeters, R.L., et al., The Novel Fold of Scytovirin Reveals a New Twist For Antiviral
Entry Inhibitors. Journal of Molecular Biology, 2007. 369(2): p. 451-461.

98.

Falb, M., et al., Structure of the K-turn U4 RNA: a combined NMR and SANS study.
Nucleic Acids Research, 2010. 38(18): p. 6274-6285.

99.

Grishaev, A., et al., Solution structure of tRNAVal from refinement of homology model
against residual dipolar coupling and SAXS data. J Biomol NMR. 2008 Oct;42(2):99-109.
Epub 2008 Sep 12., 2008.

100.

Moroder, H., et al., Non-hydrolyzable RNA-peptide conjugates: a powerful advance in
the synthesis of mimics for 3'-peptidyl tRNA termini. Angewandte Chemie, 2009. 48(22):
p. 4056-60.

101.

Geiermann, A.S. and R. Micura, Selective desulfurization significantly expands sequence
variety of 3'-peptidyl-tRNA mimics obtained by native chemical ligation. Chembiochem :
a European journal of chemical biology, 2012. 13(12): p. 1742-5.

102.

Madl, T., F. Gabel, and M. Sattler, NMR and small-angle scattering-based structural
analysis of protein complexes in solution. J Struct Biol, 2010. 173(3): p. 472-82.

103.

Zhou, J., et al., LORES: Low resolution shape program for the calculation of small angle
scattering profiles for biological macromolecules in solution. Computer Physics
Communications, 2005. 170(2): p. 186-204.

104.

Lefmann, K., Neutron Scattering: Theory, Instrumentation, and Simulation2008.

105.

Kim, J.H., D.S. Jin, and S.H. Chang, Development of safety analysis methodology for
moderator system failure of CANDU-6 reactor by thermal-hydraulics/physics coupling.
Nuclear Engineering and Design, 2013. 263(0): p. 241-254.

106.

Neylon, C., Small angle neutron and X-ray scattering in structural biology: recent
examples from the literature. Eur Biophys J. 2008 Jun;37(5):531-41. doi:
10.1007/s00249-008-0259-2. Epub 2008 Jan 23., 2008.

107.

Hauser, W. and H. Feshbach, The Inelastic Scattering of Neutrons. Physical Review, 1952.
87(2): p. 366-373.

108.

Brunger, A.T., et al., Crystallography & NMR system: A new software suite for
macromolecular structure determination. Acta Crystallogr D Biol Crystallogr, 1998. 54(Pt
5): p. 905-21.

109.

Kendrew, J.C., et al., A three-dimensional model of the myoglobin molecule obtained by
x-ray analysis. Nature, 1958. 181(4610): p. 662-6.

138

110.

Wagner, G., An account of NMR in structural biology. Nat Struct Biol, 1997. 4 Suppl: p.
841-4.

111.

Clore, G.M. and A.M. Gronenborn, NMR structures of proteins and protein complexes
beyond 20,000 M(r). Nat Struct Biol, 1997. 4 Suppl: p. 849-53.

112.

Helliwell, J.R., Synchrotron X-radiation protein crystallography: instrumentation,
methods and applications. Reports on Progress in Physics, 1984. 47(11): p. 1403.

113.

Christen, P., E. Hofmann, and A. McPherson, Review Current approaches to
macromolecular crystallization, in EJB Reviews 19901991, Springer Berlin Heidelberg. p.
49-71.

139

